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Abstract  
 
Uromodulin is the most abundant protein in urine under normal physiological conditions. This 
glycoprotein is secreted exclusively by the epithelial cells of the thick ascending limb of the loop 
of Henle. Despite an extensive and long history of research on uromodulin, a clear understanding 
of its physiological role is still lacking. 
The first aim of this thesis was to develop and characterize an assay, which enables accurate 
measurements of uromodulin levels in the urine. We then investigated the effect of a variant in 
the promoter region of the UMOD gene on the biochemistry of this glycoprotein and its plasma 
levels. We finally tried to identify the clinical and biological factors modulating the levels of 
uromodulin in urine in the general population. 
We were able to characterize a robust and cost-effective assay to measure uromodulin levels in 
the urine and established a protocol for sampling, storage and experimental processing. Studying 
the relationship between uromodulin levels, clinical and genetic factors in samples from Swiss 
and Canadian cohorts, we showed that uromodulin is a reliable biomarker for kidney tubular 
mass and function in the general population. We also showed that variants in the UMOD 
promoter in addition to influence the absolute levels of uromodulin production and secretion it 
also modulates its glycosylation pattern.  
These results contribute significantly to our understanding of the physiological role of 
uromodulin and highlight its usefulness as a biomarker for kidney function analysis. 
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Zusammenfassung 
 
Unter normalen physiologischen Bedingungen ist Uromodulin das am häufigsten vorkommende 
Protein im Urin. Dieses Glykoprotein wird ausschliesslich von den Epithelzellen des dicken 
aufsteigenden Teils der Henle-Schleife sezerniert. Trotz der ausgiebigen und langen 
Forschungsgeschichte um Uromodulin fehlt uns noch immer ein klares Verständnis seiner 
physiologischen Funktion. 
Das erste Ziel dieser Dissertation war die Entwicklung und Charakterisierung eines Tests, 
welcher präzise Messungen von Uromodulinkonzentrationen im Urin ermöglicht. Anschliessend 
untersuchten wir den Effekt einer Form der Promotor-Region des UMOD Gens auf die 
Proteinbiochemie sowie zirkulierenden Plasmalevels. Letztendlich versuchten wir klinische und 
biologische Faktoren zu identifizieren, die den Uromodulinspiegel in der gesamten Bevölkerung 
beeinflussen. 
Wir waren in der Lage ein robustes und kostengünstiges Testverfahren zu entwickeln um 
Uromodulinkonzentrationen im Urin zu messen und etablierten ferner ein Protokoll zur 
Probennahme, Probenlagerung und der experimentellen Verarbeitung. Wir zeigten mittels 
Studien über die Beziehung von Uromodulinkonzentrationen mit klinischen und genetischen 
Faktoren in schweizer und kanadischen Kohorten, dass Uromodulin als verlässlicher Biomarker 
für die Nieren(tubuläre)-Masse und -Funktion in der allgemeinen Bevölkerung genutzt werden 
kann. Wir bewiesen des Weiteren, dass genetische Varianten des UMOD Promotors neben der 
Beeinflussung der absoluten Produktions- und Sekretionsmenge von Uromodulin auch seine 
Glykosylierungsmuster modulieren. 
Die hier gezeigten Resultate tragen zum weiteren Verständnis der physiologischen Rolle von 
Uromodulin bei und untermauern dessen Nutzen als Biomarker für Nierenfunktionsanalysen. 
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I. Introduction 
 1. Kidney 
1.1 General structure 
 
Kidneys are bean-shaped organs located in the dorsal part of the abdominal cavity, one on each 
side of the lumbar spine. They are part of the urinary tract, which also includes the ureters, the 
urinary bladder, and the urethra. Kidneys are embedded in a fibrous capsule, which protects them 
from mechanical injury. There are three distinctive regions visible with the naked eye in a 
kidney: (from outside to inside) the cortex, the medulla, and the renal sinus. The cortex and 
medulla both form the renal parenchyma and encompass millions of nephrons, which are the 
functional units of the kidney. The renal sinus is a large cavity that is located below the renal 
parenchyma and opens to the exterior through the hilum across which pass the renal artery and 
vein, lymphatics, nerve supply and ureter that carries the final urine from the kidney to the 
bladder (Gyton A. et al. 2006). 
 The kidney displays a highly organized structure adapted to its homeostatic role 
combining the essential processes of filtration, secretion and reabsorption. The smallest 
functional unit of the kidney, the nephron, comprises several specialized cell types deriving from 
various embryological lineages (Figure 1). About 1 million nephrons lie in each kidney. Kidneys 
are not able to regenerate new nephrons, therefore, the number of nephrons decreases with renal 
injury, disease and age. Every nephron contains a mass of glomerular capillaries called the 
glomerulus that contains a network of capillaries lined with fenestrated epithelial cells. The 
entire glomerulus is encased in Bowman’s capsule. Large amounts of fluid are filtered through 
the glomerulus, then flowing within a long tubule made of differentiated segments in which 
reabsorption and secretion events change the composition of urine. The final parts of these 
tubules are interconnected to form the collecting ducts, which open into the renal pelvis. 
1.2 Physiology 
 
As an organ involved in excretory, metabolic and endocrine activity kidneys play an essential 
role in maintaining vital functions. Kidneys are the primary means for eliminating waste 
products and toxins from the bloodstream and excreting them through the urine. Due to their 
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extensive capacity to filter and reabsorb solutes and water, they regulate body’s fluid status, 
electrolyte balance and acid-base balance. They also produce or activate hormones that are 
involved in erythrogenesis, Ca2+ metabolism and the regulation of blood pressure and blood flow 
(Figure 2). 
 
  
Figure 1: Structure of the nephron. Adapted from Junqueira’s Basic Histology, 13e Chapter 19: The Urinary 
System. 
 
 Kidneys excrete around 1.5 L/day. They are perfused with large amount of ultrafiltrate 
(20 % of the cardiac output), which is considerably modified during tubular passage, and of urine 
thus leaving the body composition tightly affected by any changes in kidney function on one 
hand and exposing this organ to changes of the interior milieu unlike any other organ (Eckardt 
KU. et al. 2013). 
 The glomerular filtration barrier is made up of three sequential layers: the glomerular 
fenestrated endothelial cells, the glomerular basement membrane and the podocytes with their 
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foot processes enwrapping the glomerular capillaries (Haraldsson B. et al. 2008). Water, small 
solutes, and low-molecular-weight proteins  (LMW) (up to the mass of albumin, 66.5 kDa) are 
capable of crossing the filtration barrier unlike plasma proteins with a mass of more than 60-70 
kDa, especially if they are negatively charged. Thus, the ultrafiltrate leaving the glomerulus 
contains plasma solutes and several grams of LMW. The composition and the amount of this 
filtrate depend on numerous factors including the glomerular filtration rate (GFR), the product of 
the filtration area, the hydraulic permeability and the net ultrafiltration pressure. Alterations in 
glomerular haemodynamics or composition cause decreased GFR or increased leakage of 
proteins into the urine, which are both typical symptoms of renal disease. 
 As the glomerular filtrate gets into the renal tubules, it circulates progressively through 
the consecutive part of the tubule. Urine composition is affected by numerous mechanisms that 
are mediated by polarized transport systems in the epithelial cells lining the tubules. Throughout 
this course, a series of modifications takes place such as the massive reabsorption of LMW 
proteins, solutes, and water, secretion of a gel-like protein called uromodulin (Tamm-Horsfall 
protein) and elimination of excess potassium, acids and bases (Figure 1). In the proximal tubule, 
about two-thirds of the filtered solutes and water is reabsorbed. The cells lining the proximal 
tubule are equipped with multiligand receptors to carry out the endocytic uptake of filtered 
proteins (hormones, carrier proteins and enzymes) to be subsequently metabolized, as the human 
urine is protein-free under physiological conditions. This excessive protein uptake is essential for 
metabolic clearance, hormone homeostasis, and conversation of necessary vitamins (vitamin D, 
vitamin A, and vitamin B12); it also grants a milieu devoid of proteins for the cells lining distal 
nephron segments (Christensen EI. et al. 2009). In the last part of the proximal tubule, specific 
transporters drive the secretion of organic molecules and drug metabolites into the urine. 
Moreover, paracellular reabsorption of Ca²+ and Mg²+occurs in the loop of Henle under the 
control of Ca²+/ Mg²+ sensing receptors (Ferrè S. et al. 2012). Additionally, this segment of the 
tubule plays a crucial role in urine concentration by creating a hypertonic milieu in the medulla. 
The macula densa has a special structure of particular epithelial cells, located at the intersection 
between the thick ascending limb of the loop of Henle and the distal nephron. It regulates the 
glomerular blood flow through a mechanism called tubuloglomerular feedback by detecting the 
tubular NaCl concentration and interacting with the granular cells containing renin in the afferent 
arterioles (Singh P. et al. 2010). Lastly, the distal nephron, comprising the distal convoluted 
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tubule, the connecting tubule, and the collecting duct is susceptible to aldosterone and 
vasopressin (role discussed below) thus regulates the final urine composition and concentration. 
Many of the abovementioned tubular transport processes can be altered by specific drugs such as 
diuretics, aquaretics, calcimimetics, and the more recently developed inhibitors of glucose 
reabsorption (Reilly R. et al. 2000). 
 
Figure 2: Effect of kidney function on essential homoeostatic processes. FGF: fibroblast growth factor. 
ANF: atrial natriuretic factor. Adapted from Eckardt KU. et al. 2013. 
 
NaCl excretion, a critical solute for extracellular fluid volume and blood pressure regulation, is 
controlled by the renin-angiotensin-aldosterone system, the atrial natriuretic peptide, the 
sympathetic nervous system and to a slighter extent by antidiuretic hormone arginine 
vasopressin. However, the excretion of potassium depends mostly on the distal tubular flow rate 
and on the release of aldosterone and its action on the principal cells of the distal nephron. 
Vasopressin is involved in controlling osmoregulation by acting on aquaporin-mediated transport 
of water (Stockand JD. et al. 2010; Schrier W. et al. 2008). A more complex interaction between 
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bone, parathyroid glands, intestine and tubular segments delineate the balance between 
phosphorus and calcium involving fibroblast growth factor (FGF), klotho, parathyroid hormone, 
and vitamin D. Moreover, kidneys manage tissue oxygen supply via hypoxia-inducible 
erythropoietin production in peritubular fibroblasts of the renal cortex a role that makes the 
kidneys the main site of systemic oxygen sensing (Kurosu H. et al. 2008; Martin A. et al. 2012). 
1.3 Pathophysiology 
 
Kidney disease occurs when the structure and/ or the function of this organ is altered. Even the 
slightest disorder can increase the risk of kidney failure or lead to a series of complications in 
other organ systems, especially the cardiovascular system. The clinical manifestations and 
disease progressions are diverse. Depending on the duration, kidney disease can be classified as 
acute (within days) or chronic. Acute kidney injury and chronic kidney disease are associated: 
acute kidney injury can evolve to chronic kidney disease, and chronic kidney disease amplifies 
the risk of acute kidney injury (Chawla L. et al. 2012). 
1.3.1 Chronic kidney disease 
 
Chronic kidney disease (CKD) is a complex and developing disease associated with high 
mortality and high cost of care. In the last years, CKD prevalence has increased because of the 
high incidence of risk factors such as cardiovascular diseases, diabetes, aging as well as the 
occurrence of acute kidney injury in the general population. The Kidney Disease: Improving 
Global Outcomes (KDIGO) guidelines bring the focus on the estimation of GFR from serum 
creatinine and monitoring markers of kidney damage (primarily albuminuria). Additionally, the 
use of standardized assays for creatinine and more accurate equations to estimate GFR were 
incorporated (Levey AS. et al. 2006; Levey AS. et al. 2009). Furthermore, cystatin C levels were 
added as a variable to estimate GFR and prognosis (Inker LA. et al. 2012). In 2013, albuminuria 
measurement was acknowledged by the KDIGO as an important marker for prognosis (Miller G. 
et al. 2009; Matsushita K. et al. 2012). The severity of CKD can be classified into 5 stages (Table 
1). Stage 5 or end-stage renal disease (ESDR) involves in most of the case renal replacement. 
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Stage of Chronic Kidney Disease of all Types 
Stage Qualitative  
description 
Renal Function 
(ml/min/1.73 m2) 
1 Kidney damage – normal GFR ≥ 90 
2 Kidney damage – mild    GFR 60-89 
3 Moderate    GFR 30-59 
4 Severe    GFR 15-29 
5 End-stage renal disease <15 (or dialysis) 
 
Table 1: The five stages of chronic kidney disease. Adapted from 
http://guidelines.diabetes.ca/browse/chapter 29 
 
1.3.2 Acute kidney injury 
 
Acute kidney injury (AKI) is known as a sudden decrease in kidney function. The clinical 
manifestation of AKI is characterized by a rapid decrease in GFR, leading to alteration in 
electrolyte and acid-base balance. In addition to disturbances of extracellular fluid volume, 
hindrance of nitrogenous waste products and in most cases a decline in urine output (Bellomo R. 
et al. 2004). There has been controversy about ways to best evaluate kidney function this 
included markers that reveal best the decline in renal function and their levels to distinguish 
normal from abnormal renal function. The AKI KDIGO guideline relies on previous attempts to 
identify the disorder and focus on deviations in serum creatinine or drop in urine output as 
indicators of direct injury to the kidney and acute damage of function. In contrary to chronic 
kidney disease, the definition of acute kidney injury does not comprise markers of impairment, 
but rather a thorough analysis of urinary biomarkers preceding the decrease in GFR (e.g. kidney 
injury molecule 1, neutrophil gelatinase-associated lipocalin, and interleukin 18), thus grant a 
possible early detection and treatment (Chawla L. et al. 2012). 
1.3.3 Genetic predisposition to kidney disease 
 
The genetic architecture of kidney diseases includes Mendelian (monogenic) and complex 
diseases. Mendelian diseases are rare in the general population. Mutations in a single gene are 
sufficient to cause the manifestation of the disorder. In this type of diseases, only individuals 
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with a mutation in the causative gene are at risk for expressing the disorder. In contrast, complex 
disorders are common in the general population. In these diseases, genetics has a significant role 
but the display of the disease is due to interaction between genetic and environmental risk 
factors. Therefore, complex disorders do not show distinct inheritance patterns as in Mendelian 
disorders (Pritchard JK. et al. 2001). Thanks to classic and next-generation sequencing, more 
than hundred genes have been associated with monogenic kidney diseases. A classic example of 
these disorders is autosomal-dominant polycystic kidney disease (ADPKD), the most frequent 
monogenic renal disorder (Hildebrandt F. et al. 2010). Identification of a single-gene mutation 
underlying renal disease in families has become easier with the access to the whole exome and 
whole-genome sequencing. Moreover, with these techniques, investigation of the added effect of 
rare mutations and common disease susceptibility variants could be of help in explaining high 
phenotype heterogeneity, which are observed in several monogenic renal disorders. Genetic and 
environmental components shape the predisposition to complex multifactorial diseases such as 
chronic kidney disease. Genome wide association studies (GWAS) and admixture linkage 
disequilibrium methods assisted in identifying predisposing variants. Also; they favored the 
identification of genomic regions that have increased association with intermediate traits in the 
general population such as GFR, albuminuria and CKD. Furthermore, certain genomic regions 
are well known to be linked to specific renal diseases such as non-diabetic end-stage renal 
disease or focal-segmental glomerulosclerosis (Chambers J. et al. 2010; Köttgen A. et al. 2010). 
It is speculated that genetic risk variants can have a range of consequences (from small to large 
effects) on disease severity and this idea is becoming more convincing. Uromodulin is a good 
example of this: single mutations in the uromodulin (UMOD) gene are responsible for 
monogenic kidney disease (known as uromodulin-associated kidney disease) (Hart TC. et al. 
2002), whereas specific common variants in the same gene increase predisposition to CKD, 
hypertension and many other complex renal phenotypes in the general population (Köttgen A. et 
al. 2009; Devuyst O. et al. 2017). Several rare inherited disorders shed light on common 
disorders of renal function. Monogenic diseases causing disturbances in sodium handling in the 
kidney helped understanding blood pressure regulation and mechanisms of action of diuretics (Ji 
W. et al. 2008; Devuyst O. et al. 2008) whereas disorders affecting proximal tubule like Fanconi 
syndrome highlighted the role of receptor-mediated endocytosis in acquired proximal tubule 
dysfunction and disease progression (Devuyst O. et al. 2010). Advanced knowledge about the 
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genetic components in kidney disease helps in making treatment decisions. For instance, 
identifying a genetic cause for a disorder in glomerular filtration barrier would aid in preventing 
improficient exposure to steroid treatment among children with nephrotic disorder. 
2. Biomarkers for renal and tubular function 
 
2.1 Biomarker: properties and role 
 
Biomarkers are biological parameters that can be objectively measured and evaluated. They 
reflect physiological processes, pathological mechanisms or pharmacological responses to a 
therapy. A good biomarker is easily and inexpensively measured from an accessible source 
(blood, urine, cerebral spinal fluid etc.) with high sensitivity and specificity favoring an early 
detection of a particular disease, stratification for a certain risk as well as treatment monitoring. 
Major efforts have been made to explore and identify better biomarkers for disease prognosis 
hence better care for people at high risk for disease occurrence (McMahon G. et al. 2013). 
 Urinary biomarkers have been conventionally used to diagnose kidney disease, such as 
the presence of albuminuria which is a result of glomerular damage. Urine remains a better 
source of biomarkers in comparison to plasma. It can be noninvasively and continuously 
collected and it comprises plasma proteins that were filtered through the glomerulus as well as 
proteins secreted by the kidneys. Thus the urinary proteome directly reflects the condition of the 
urinary system in addition to some changes in the plasma proteome. Therefore, urine is an ideal 
source to study urological diseases at the same time it conveys information about the status of the 
entire body. Identifying potential biomarkers diseases in the urine, as the main component of 
investigative medicine, has gained a lot of attention in the last few years. Present studies focus on 
urogenital diseases (chronic and acute renal injuries, transplant rejection, bladder and prostate 
cancer). In addition, changes in the urinary proteome were also shown to be related to some 
systematic diseases, such as diabetes and coronary artery disease. These efforts used identified 
pathophysiology of the disease to detect a potential biomarker that is verified in clinical trials 
afterwards. A new approach had emerged in biomarker discovery with the advancement of 
protein mass spectrometry where the discovery of biomarkers is done by large-scale profiling on 
the protein content of the urine. This work revealed the display of more than 1000 gene products 
and numerous peptide fragments of large proteins. Thus, mass spectrometry offers the possibility 
to determine a urinary protein excretion profile which is clinically useful in early detection and 
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classification of several diseases as well as prognosis and monitoring of specific treatment (Shao 
C. et al. 2011). 
2.2 Available urinary biomarkers for renal function and disease 
 
Many conventional and novel biomarkers have been acknowledged for kidney disease prognosis 
and diagnosis. In this section, we will only discuss urinary biomarkers; these biomarkers reside 
mainly in the protein phase of the urine that consists of insoluble (48 % sediments and 3 % 
exosomes of total urinary protein) and soluble (49 % of the total urinary protein) proteins (Zhou 
H. et al. 2006). 
2.2.1 Conventional biomarkers 
 
This category includes filtration markers, such as creatinine and cystatin C, as well as markers of 
kidney damage, like urine sediment abnormalities and albuminuria (Table 2). 
Creatinine: It has been adopted as a marker of GFR since many years. It is considered as 
a good marker of glomerular filtration since it is not metabolized in the kidney, and is freely 
filtered in the glomerulus. Nevertheless, the use of this marker in CKD and AKI is limited by the 
non-GFR determinants of creatinine concentration such as the secretion by the proximal tubule, 
degradation by the gut bacteria and reabsorption in patients with very low urine and tubular flow 
rates and in the case of certain medications. There are other factors such as gender, age, race, 
muscle mass and many others that affect creatinine secretion thus limiting its use for GFR 
estimation. To estimate GFR (eGFR) accurately and to overcome inter-person variability few 
creatinine-based equations have been developed. Despite these improvements, all the equations 
allowing to calculate eGFR have drawbacks, by either overestimating or underestimating GFR 
(Sandilands E. et al. 2013). 
Cystatin C: It is a cysteine protease inhibitor that gets fully degraded locally in the renal 
tubules after glomerular filtration and proximal tubular reabsorption. Unlike creatinine, cystatin 
C is not actively secreted through the kidney and has no significant extrarenal elimination; also it 
is not influenced by changes in muscle mass which makes it an excellent marker, superior to 
creatinine, for renal function and accurately estimating GFR. Additionally, the presence of 
cystatin C in the urine suggests some form of proximal tubular injury indicating urinary cystatin 
C as a potential marker of acute tubular injury. Cystatin C excretion, as other low molecular 
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weight (MW) urinary biomarkers, is affected by increasing levels of albuminuria because of the 
competitive inhibition of cystatin c uptake in the presence of albuminuria. Different assays and 
methods exist to measure cystatin C but all are limited by the significant interassay variation, 
with some assays performing better for the diagnosis of AKI and CKD (Edelstein C. et al. 2011; 
Nejat M. et al. 2012; Inker L. et al. 2012). 
Urinary protein: Proteins of the soluble phase originate mainly from glomerular filtration. 
High MW proteins are effectively retained by the glomerular filter due to the low sieving 
coefficient. Despite this process, proteins that are abundant in plasma such albumin can still 
cross the glomerular filter into the lumen of the nephron. Furthermore, small proteins with MW 
below 60 kDa as well as peptides can freely pass through the glomerular filter. Considerable 
amount of the filtered proteins and peptides are removed from the lumen of the nephron by 
specific apical uptake processes including receptor-mediated endocytosis. Accordingly, any 
modification in the level of certain soluble protein in the urine may indicate a variation in its 
amount in the plasma, alteration in the glomerular filtration or changes in the uptake system by 
the proximal tubule. Consequently, a modified excretion rate of a specific protein may designate 
a systemic disorder, glomerular impairment or a pathological state (Christensen EI. et al. 2001; 
Christensen EI. et al. 2002). 
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Table 2: Use and limitations of conventional biomarkers. AKI: acute kidney injury; eGFR, estimated 
glomerular filtration rate; ESRD, end-stage renal disease. Adapted from McMahon G. et al. 2013. 
 
2.2.2 Novel biomarkers 
 
Levels of conventional biomarkers increase relatively late during injury processes, thus 
preventing prognosis and limiting early intervention that might circumvent disease progression. 
Moreover, conventional biomarkers in most of the cases do not allow anatomical location of the 
injury; the majority of these biomarkers reflect glomerular function and proximal tubule activity 
whereas other segments of the nephron are underrepresented. Therefore, novel biomarkers are 
needed for early and specific identification of alterations in the different parts of the nephron 
(Figure 3). These novel biomarkers will allow precocious intervention, improved stratification 
 Uses Limitations 
Creatinine • Glomerular filtration marker 
• eGFR estimation 
• Biomarker of acute and chronic 
reduced kidney function 
• Variability in generation rates across 
individuals 
• Significant tubular secretion leading to 
overestimation of GFR 
• Significant extra-renal elimination 
• Tubular reabsorption in low urine flow states 
• Increases late after AKI 
Cystanin C • GFR estimation (plasma) 
• Biomarker of proximal tubular 
dysfunction (urine) 
• Biomarker of acute and chronic 
reduced kidney function 
• Increases late after AKI 
• May increase in inflammatory states or in 
 thyroid dysfunction independent of kidney 
function 
• Urinary Cystatin C is altered in the presence 
 of albuminuria 
Albuminuria • Biomarker of glomerular 
filtration barrier dysfunction 
• Biomarker of proximal tubular 
dysfunction 
• Early biomarker of AKI 
• Independent risk factor for 
- cardiovascular 
- all-cause mortality- and ESRD 
• 24 h collections unreliable 
• Significant intra-individual variability in 
albumin/ creatinine ratio over short time 
periods 
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and good monitoring of treatment efficiency (McMahon G. et al. 2013). These biomarkers help 
identifying and classifying renal diseases with various clinical conditions depending on their 
anatomical expression. i.e. lipocaline-2 or neutrophil gelatinase-associated lipocalin (NGAL), 
Interleukin 18 (IL-18) and Kidney Injury Molecule 1 (KIM-1) are biomarkers for AKI; 
Asymmetric dimethylarginine (ADMA), β-trace protein (BTP), L-type fatty acid binding protein 
(L-FABP) are biomarkers for CKD; monocyte chemotactic peptide-1 (MCP-1) (combined with 
NGAL), α-1-acid glycoprotein, and ceruloplasmin for glomerular disease (Edelstein C. et al. 
2011; Nejat  M. et al. 2012; Ozer J. et al. 2010). 
Lipocalin-2 (LCN2): it is a 21 kDa protein expressed primarily by immune cells, 
hepatocytes and renal tubular cells. It can be readily detected in the urine and is protease-
degradation resistant. This makes it an ideal biomarker for AKI. LCN2 appears in the urine 
shortly after a hypoxic injury but once AKI is resolved, both plasma and urinary NGAL levels 
return to baseline. In addition to AKI, LCN2 could also be a convenient biomarker for CKD 
especially for identifying CKD patients at risk of a significant decline in GFR, since it is highly 
sensitive to subtle changes in tubular function. Urinary and serum LCN2 levels are increased in 
many kidney diseases including IgA nephropathy, autosomal dominant polycystic kidney disease 
and diabetic nephropathy (Mishra J. et al. 2003; Haase M. et al. 2011). 
KIM-1: A transmembrane protein expressed at very low levels in normal kidney. Under 
ischemic condition or nephrotoxic AKI dedifferentiated proximal tubular cells increase the 
expression of KIM-1 and let the extracellular domain of KIM-1 appear in the urine succeeding 
ischemic injury. KIM-1 levels can be detected easily by urinary dipstick, making it a suitable and 
available biomarker of AKI. Moreover, increased urinary KIM-1 levels predict an elevated risk 
of mortality or necessity for dialysis in hospitalized patients with AKI. As a biomarker of AKI 
KIM-1 may be more reliable in patients with normal baseline kidney function, as is the case for 
many novel biomarkers. This could be due to its upregulation in many chronic kidney diseases 
with the degree of expression associated with tubulointerstitial fibrosis. Its role in CKD is under 
investigation (Han WK. et al. 2002; Bonventre J. et al. 2009). 
IL-18: it is a pro-inflammatory cytokine expressed mainly by macrophages but also by 
monocytes, dendritic cells and kidney epithelial cells. It is implicated in the innate and adaptive 
immune reaction and is upregulated in inflammatory conditions. Due to its expression by kidney 
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tubular epithelium urinary IL-18 was suggested as a potential marker of AKI. It is believed that 
IL-18 is one of the mediators of injury in ischemic AKI as its interstitial expression was proved 
to increase in mouse models of AKI whereas IL-18 Inhibition has been accompanied by recovery 
from inflammatory disease. Moreover, in models of ischemia, it has been shown that mice 
deficient in caspase, an IL-18-activating enzyme, were less prone to develop acute tubular 
necrosis than wild-type mice. The early increase in IL-18 levels in patients with sepsis in the 
intensive care unit makes it a good predictor of AKI, particularly when combined with NGAL. 
IL-18 may be a more general marker of inflammation rather than a specific marker of AKI, 
mainly in elderly where baseline reduced kidney function underlies (Parikh CR. et al. 2004; 
Parikh CR. et al. 2006).  
 
Figure 3: Anatomical localization of biomarkers along the nephron. Abbreviations: GST: Glutathione S- 
transferase; CTGF: Connective tissue growth factor; NGAL: Neutrophil gelatinase-associated lipocalin; 
ADMA: Asymmetric dimethyl arginine; KIM-1: Kidney injury molecule 1; L-FABP: Liver-type fatty acid 
binding protein; GGT: Gamma-glutamyl transpeptidase; IL-18: Interleukin 18; LDH: lactate 
dehydrogenase; NAG: N-acetyl glucosaminidase. Adapted from McMahon G. et al. 2013. 
 
The joint efforts of basic science investigations and modern clinical epidemiology techniques 
helped to discover and validate novel biomarkers of kidney disease. Before largely implementing 
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the newly identified biomarkers in the clinic it is crucial to test those in larger studies with 
clinically important endpoints. It will be also required to compare conventional versus novel 
biomarkers for their added clinical utility as well as their correlation to the severity of disease 
with biomarker levels and duration of elevation. Additionally developing reliable assays will 
facilitate their measurements. 
3. Uromodulin 
 
Uromodulin has been first described in 1873 by Carlo Rovida and named as cilindrina. In 1950 
Tamm and Horsfall described the same mucoprotein as they were able to purify it from urine and 
they reported its inhibitory effect to viral hemagglutination. Tamm-Horsfall protein is the most 
abundant protein in urine under physiological conditions and can form a gel-like structure 
(Devuyst O. et al. 2017). 
3.1 Biology of the protein: Structure and biosynthesis 
 
3.1.1 Structure and Maturation: The precursor of uromodulin has 640 amino acids before 
entering the endoplasmic reticulum (ER) where it gets glycosyl-phosphatidylinositol (GPI) 
anchored and glycosylated. After this step, it travels to the apical plasma membrane of epithelial 
cells where it gets cleaved to join the lumen. The processing step in the ER is the longest during 
protein maturation due to the complex tertiary structure attributed to the high number of cysteine 
residues (7 % of amino acid content) which are all involved in the formation of intramolecular 
disulfide bonds (Serafini-Cessi F. et al. 1993). The GPI-anchored protein has a molecular weight 
of 100 kDa (reduced condition) of which 30 % is credited to N-glycans. Confirmation of O-
glycosylation has also been described (Easton RL. et al. 2000). The high glycan content provides 
the protein with several chemical and physical properties, thus various roles. Uromodulin is 
composed of several domains: a leader peptide that allows its entry into the secretory pathway, 4 
epidermal growth factor-like domains (EGF-II and EGF-III are predicted to be calcium-binding 
domains) these modules are important for protein-protein interaction (Bokhove M. et al. 2016), a 
central domain with unknown function and it contains 8 conserved cysteines and a zona 
pellucida (ZP) domain that is essential for protein polymerization based on the ionic conditions 
(Jovine L. et al. 2002) (Figure 4). 
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Figure 4: A: Uromodulin has a main peptide (grey), 4 epidermal growth factor (EGF)-like domains 
(orange), a cysteine-rich D8C domain of yet unknown function (red), bipartite zona pellucida (ZP_N and 
ZP_C) domain (blue), and glycosyl-phosphatidylinositol (GPI)–anchoring site at position 614 (green). The 
7 N-glycosylation sites are indicated in triangles. The high-mannose chain site on residue Asn 274 is 
indicated with a red triangle. Adapted from Devuyst O. et al. 2017. B: Model of uromodulin maturation, 
excretion and polymerization. Uromodulin is produced by the epithelial cells of the TAL. In the 
endoplasmic reticulum it gets GPI-anchored, N-glycosylated and the disulfide bonds are formed. In the 
Golgi apparatus all N-glycosylated chains are modified except the one on Asn 274 that keeps the high-
mannose moiety. On the plasma membrane polymerization-incompetent uromodulin is cleaved by a 
protease hepsin to join the lumen where it gets polymerized to form filaments. Adapted from Rampoldi L. 
et al. 2011. 
 
3.2.1 Localization and Secretion: Uromodulin is exclusively expressed by the epithelial cells 
lining the thick ascending limb (TAL) of Henle’s Loop. It is mainly detected at the apical plasma 
membrane, although localization at the basolateral side of TAL cells has also been reported 
(Bachmann S. et al. 1985; Peach RJ. et al. 1988). Studies on uromodulin trafficking in 
transfected polarized epithelial cells in addition to evidence its presence at very low 
concentrations in the blood compared to urine (ng vs µg) suggest its release from the basolateral 
side (Jennings P. et al. 2007). Uromodulin transcripts are documented from embryonic day 16.5 
in the developing mouse kidney (Chen Y. et al. 2006) whereas in humans, the protein is 
A 
B 
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identified from gestational week 16 by immunohistochemistry analysis and from week 20 in the 
amniotic fluid (Zimmerhackl LB. et al. 1996). Its secretion increases progressively with time and 
maturation of TAL tubules until birth. In mature TAL cells, uromodulin is the most abundant 
transcript and has a short half-life (about 9 h in rabbit and 16 h in humans) (Grant M. et al. 1973; 
Serafini-Cessi F. et al. 2003). A person can produce approximately between 50-150 mg/day 
under physiological conditions (Chabardes GD. et al. 2003). A conserved proteolytic cleavage is 
essential to release uromodulin from the apical plasma membrane into the tubule’s lumen 
(Santambrogio S. et al. 2008) and is crucial for protein polymerization since it releases an 
inhibitory motif that prevents premature protein assembly (Schaeffer C. et al. 2008). The protein 
is released in the lumen after cleavage by type II transmembrane serine protease hepsin (Brunati 
M. et al. 2015) where it can form a network of filaments and small fibrils with a width of about 
100 Å and average length of 25,000 Å that tend to aggregate (Porter K. et al. 1955). Filaments of 
uromodulin are arranged in a double helix with a diameter of 90 to 120 Å (Jovine L. et al. 2002).  
3.1.3 Expression and Conservation: Uromodulin is present in the kidney of all mammals. 
UMOD is located on chromosome 16p12.3-16p13.11 and is spread over 20 Kb it has 11 exons 
(exon 1 is non-coding). Its transcription is driven by a promoter (3.7 kbp), of which a large part 
(the first 589 bp) is highly conserved in mammalian species (Pook MA. et al. 1993). It is 
suggested that this region harbours the required cis-regulatory elements for UMOD expression in 
the nephron. Studies have proved that the 5’ proximal flanking region of UMOD is highly 
conserved between mice, rats and humans (Zhu X. et al. 2002). In silico exploration of the 
upstream region of UMOD showed numerous conserved binding motifs among studied primates 
and rodent species suggesting relevant transcription factors expressed in the kidney that might 
regulate the expression of uromodulin (Srivastava R. et al. 2014). UMOD gene is CpG rich but 
not in the promoter region which implies a possible epigenetic regulation of uromodulin 
(Rosenbloom K. et al. 2015). There is a similarity between uromodulin sequence and domain 
composition with one of glycoprotein-2 (GP-2) that is the major component of zymogen granule 
membranes of exocrine pancreas, and liver-specific ZP domain-containing protein. Genes of 
both, GP-2 and UMOD lie adjacent on chromosome 16p12.3, suggesting that they could have 
evolved from a common ancestral gene (Fukuoka S. et al. 1992) (Figure 5). Like uromodulin 
(see below), GP-2 is capable of binding Escherichia Coli (E. Coli) of the fimbriated type I, 
proposing that both proteins have similar protective functions against microorganisms in the 
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urinary and digestive system (Yu S. et al. 2009). Anti-uromodulin immunoreactivity was 
reported in the kidneys of mammals, in layers of the skin of several amphibians and fishes, and 
in the distal tubules of the kidney of some amphibians (Howie AJ. et al. 1993). Comparative 
genomic analysis acknowledges UMOD homologs in amphibian (Xenopus tropicalis) and fish 
(Danio rerio) genomes, with significant sequence similarity at the predicted protein level. The 
function of these homologs and their relevance for comparative physiology remain to be 
determined. 
 
 
Figure 5: Evolution of UMOD gene. Phylogenic tree shows the assumed evolutionary relationship between 
uromodulin and glycoprotein 2. Adapted from Devuyst O. et al. 2017. 
3.2 Physiology of uromodulin 
 
The exact physiological role of uromodulin is still to be defined. However, multiple 
investigations have suggested that the glycoprotein may have many physiological functions 
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(Figure 6) due to its highly variable post-translational modifications, GPI-anchoring and multiple 
domains. 
3.2.1 Water homeostasis: The particular formation of filamentous gel-like structures of 
uromodulin on the luminal plasma membrane of epithelial cells in the TAL may serve as a 
physical barrier (polyanionic gel) to water permeability and can be implicated in maintaining the 
countercurrent gradient in the interstitium. Additionally, Umod-knockout mice exhibited urine 
concentration disabilities after water deprivation (Bachmann S. et al. 2005). 
3.2.2 Salt handling and blood pressure regulation: Uromodulin may have a role in water/ 
electrolyte balance in the TAL, this hypothesis is supported by Mutig et al. In his work Mutig et 
al. showed that intracellular trafficking of furosemide-sensitive Na-K-2Cl cotransporter 
(NKCC2) to the apical surface of the TAL is enhanced by uromodulin: An increase in 
uromodulin production is associated with increased NKCC2 expression and sodium reabsorption 
(Mutig K. et al. 2011) a fact evidenced by Trudu et al. (Trudu M. et al. 2013). Moreover, 
Renigunta et al. confirmed the significant increase of the activity of renal outer medullary 
potassium channel (ROMK2) with the expression of uromodulin. There is a direct interaction 
and positive regulation of its delivery to the plasma membrane. In another data set, it was 
highlighted that the lack of uromodulin in Umod-knockout mice resulted in a significant 
upregulation of ROMK2, a consequence of a reduction of the number of channels at the plasma 
membrane and their increase in the vesicular pool (Renigunta A. et al. 2011). Further 
investigation is needed to prove the specificity of this effect on ROMK since ion transporters of 
downstream segments (Na-Cl cotransporter, a-epithelial Na channel) were also found to be 
significantly upregulated in uromodulin-deficient mice (Bachmann S. et al. 2005). 
3.2.3 Protection against urinary tract infection (UTI): Uromodulin gel-like structure may also 
be involved in other advantageous functions such hindering the epithelial binding of 
uropathogenic bacterial in UTI. N-linked high mannose chains of uromodulin compete for the 
binding with uroplakin receptors from E.Coli and prevent their adherence to glycoproteins and 
glycolipids of the luminal plasma membrane thus conferring protection against UTI (Chabardes 
GD. et al. 2003). Mo. et al. showed that Umod-knockout mice have increased susceptibility to 
UTIs (Mo L. et al. 2004). In humans, Wolf et al. reported recurrent UTIs in children with UMOD 
mutations (Wolf MT. et al. 2006), whereas as Garimella et al. showed an association between 
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high urinary uromodulin levels and lower risk for UTI in older community-dwelling adults 
independent of traditional UTI risk factors (Garimella S. et al. 2016). 
3.2.4 Protection against stone formation: It has also been suggested that uromodulin reduces 
the aggregation of calcium oxalate crystals via its sialylated and negatively charged glycans thus 
acts as an inhibitor of urinary stone formation. In Umod-knock-out mouse models an increased 
tendency for calcium crystal formation and a reduced ability to inhibit the adhesion of calcium 
oxalate monohydrate crystals to renal epithelial cells has been documented. Similarly, 
uromodulin deficiency in humans may be a risk factor for nephrolithiasis (Grant A. et al. 1973; 
Serafini-Cessi F. et al. 2003). In addition to its inhibitory role for crystal formation, uromodulin 
might influence the paracellular handling of calcium in the TAL (since it can modulate TAL 
activity). It can also stabilize the calcium channel transient receptor potential cation channel 
subfamily V member 5 (TRPV5) in the DCT thus potentially influencing the urinary 
concentration of calcium phosphate, calcium oxalate as well as calcium excretion (Wolf MT. et 
al. 2013). 
3.2.5 Immunomodulation and protection against acute kidney injury: Another protective 
role has been attributed to uromodulin in acute kidney injury by decreasing inflammation and 
improving recovery. Umod-knockout mice evidenced more functional and histological kidney 
damage and showed late recovery after ischemia-reperfusion injury in comparison to wild-type 
mice. In wild-type animals exposed to ischemia-reperfusion injury uromodulin accumulated at 
the basolateral side of TAL cells that is in close contact with cells from the proximal S3 segment. 
This observation highlights a protective role of UMOD mediated by cross-talk between segments 
possibly by binding and inhibiting components of the immune system via N-linked-carbohydrate 
sequences (El-Achkar TM. et al. 2011). The same group showed a downregulation in uromodulin 
expression at the peak of acute kidney injury, but an upregulation 48 h after ischemia-reperfusion 
injury. These findings need to be validated in humans (El-Achkar TM. et al. 2008). Of note, the 
GPI-enriched domain of UMOD may also have a receptor-like function in endocytosis which 
may implicate a role in signal transduction and cell surface event modulation (Sabharanjak S. et 
al. 2002). Finally, several in vitro studies proved that uromodulin can bind, interact with and 
activate immunity-related molecules, such as immunoglobulin G, complement 1q, and tumor 
necrosis factor α (Rhodes DC. et al. 1993; Rhodes DC. 2000; Hession C. et al. 1987), indicating 
that uromodulin may play a role in innate immunity of the kidney. Also, through interacting with 
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and activating components of the immune system, monocytes, neutrophils, and myeloid dendritic 
cells via toll-like receptor 4 uromodulin can act as a chemoattractant as well as a 
proinflammatory molecule (Säemann MD. et al. 2005; Schmid M. et al. 2010). Tubulointerstitial 
nephritis was induced in rabbits, rats, and mice after uromodulin supplementation (Mayrer R. et 
al. 1982; Hoyer JR. 1980). Anti-uromodulin antibodies were observed in mice, as a result of toll-
like receptor 4 functions (Säemann MD. et al. 2005). Taking together the above- mentioned facts 
evidence an association between interstitial uromodulin release and inflammatory cell infiltration 
as well as the increase in uromodulin-specific autoantibodies in several inflammatory disorders 
and infections of the urinary tract (Säemann MD. et al. 2005). This indicates that uromodulin 
could act as a danger-sensing molecule which can trigger an inflammatory response in the 
presence of potential injury or damage to the nephron integrity. Nevertheless, the 
proinflammatory role of uromodulin remains debatable. El-Achkar et al. proved that Umod-
knockout mice develop more functional and histological renal damage after ischemia-reperfusion 
injury compared to wild-type animals (El-Achkar TM. et al. 2008). 
3.2.6 Cast nephropathy: In a disorder context, uromodulin constitutes a milieu for hyaline cast 
and proteinaceous cast, which are associated with low-molecular-weight proteinuria (Sanders 
PW. et al. 1990). The interaction between uromodulin and free light chains results in the 
precipitation of the latter in the distal tubule evolving into casts that cause obstruction and 
tubulointerstitial damage (Ying WZ. et al. 2012). 
 
 
 
Figure 6: proposed physiological roles of uromodulin. Animal studies using Umod-knockout mice 
suggested that uromodulin modulates blood pressure, urine concentration and might play a role in protection 
against urinary tract infections and stone formation (UTIs) as well as in activating the immune system. 
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NKCC2: sodium–potassium–chloride co-transporter, ROMK: Renal outer medullar potassium channel, 
TLR4: Toll-like receptor 4. TRPV5: transient receptor potential cation channel. Adapted from Devuyst O. 
et al. 2017. 
3.2.7 Uromodulin as a biomarker 
3.2.7.1 Congenital disorder: Urinary uromodulin has been suggested as an in utero biomarker for 
fetal tubular development and to predict AKI of newborns since it is secreted by human fetal 
tubul but cannot cross the placental barrier. In prenatal Bartter cases, uromodulin is dramatically 
reduced when compared to levels from cases with postnatal Bartter (Zimmerhackl LB. et al. 
1996; Askenazi D. et al. 2016; Schröter J. et al. 1993). 
3.2.7.2 Tubular function and eGFR: Previous separate studies have shown decreased levels of 
uromodulin in subjects with tubular damage, in the presence of ADPKD as well as in 
tubulointerstitial nephritis (Lynn KL. et al. 1984; Thornley C. et al. 1985; Tsai C. et al. 2000). 
Moreover, in recent investigations Ledo et al. presented in an expression study a strong 
correlation between uromodulin mRNA expression levels and eGFR values in CKD vs control 
subjects while Garimella et al. described in a study involving elderly that a decrease in 
uromodulin levels indicates a risk for progressive renal disease and mortality (Ledo N. et al. 
2015; Garimella PS. et al. 2015). 
3.2.7.3 Acute kidney injury (AKI): In a clinical study, investigating AKI onset after cardiac 
surgery uromodulin has been suggested as a biomarker for AKI. Low uromodulin levels were 
associated with elevated risk for AKI in post cardiac surgery subjects implying that uromodulin 
levels might reflect poor tubular health at baseline, or suggesting a protective role of uromodulin 
against AKI (El‑Achkar TM. et al. 2008; Garimella PS. et al. 2017). 
3.3 Pathophysiology of uromodulin 
 
3.3.1 Monogenic disorders: Mutations in the UMOD gene have been shown to cause medullary 
cystic kidney disease type 2, familial juvenile hyperuricemic nephropathy and glomerulocystic 
kidney disease which are collectively referred to autosomal dominant tubulointerstitial kidney 
disease uromodulin-related (ADTKD-UMOD) with an estimated prevalence of 1:100.000 
(www.orpha.net). Incomplete penetrance and de novo mutations may explain the absence of a 
family history in some patients (Hart TC. et al. 2002). So far, 125 UMOD mutations have been 
described of which 120 are missense mutations. 60 % of the total mutations affect the cysteine 
residues. Most of these mutations found in exons 3 and 4 and occur in the N-terminal half of the 
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protein (Devuyst O. et al. 2017). These mutations have a significant impact on the maturation 
and the trafficking of uromodulin causing its retention in the ER along with decreased expression 
at the plasma membrane, and declined secretion into the tubular lumen (Rampoldi L. et al. 2003). 
The intracellular buildup of the misfolded mutant protein in the ER of TAL cells results in 
cellular damage that can stimulate an immune response translated by immune cell infiltration and 
production of pro-fibrinogenic lymphokine in the tubule interstitium (Vyletal P. et al. 2006; 
Bernascone I. et al. 2010). Schaeffer et al. showed in a recent work that mutant UMOD retained 
in the ER and degraded via the proteasome pathway interacts with several ER chaperones, 
implying that uromodulin crosses the calnexin cycle to be properly folded. By transcriptional 
profiling, they proved that expression of mutant uromodulin mainly affects ER function, together 
with protein folding and ER-associated degradation (ERAD) and induces stress response. They 
also showed that ER stress activates the UPR perturbing ER homeostasis and thus reducing the 
amount of protein entering the ER while increasing ER folding capacity and ERAD (Schaeffer 
C. et al. 2017). These studies demonstrate that ADTKD-UMOD is an ER storage disease. 
Despite these findings, a clear mechanism of the progressive tubulointerstitial injury in ADTKD-
UMOD is not well-understood yet. All ADTK diseases exhibit interstitial fibrosis, tubular 
atrophy and dilation, thickening and lamellation of tubular basal membranes. A typical 
characterization of ADTKD-UMOD is the decrease in urate fractional excretion causing 
hyperuricaemia and often gout. ADTKD-UMOD has a heterogeneous clinical presentation of 
symptoms, age at onset, presence of cysts, and rate of progression to end-stage renal disease. 
Currently, the only available treatment is renal replacement therapy (Bollée G. et al. 2011; 
Eckardt KU. et al. 2015). 
Uromodulin has been associated with various renal defects: It has been found to accumulate in 
cast nephropathy, to deposit in the renal interstitium in reflux nephropathy, renal allografts 
rejection and interstitial diseases. UMOD deposits were in some cases associated with 
inflammatory infiltrate (Resnick JS. et al. 1978; Zager RA. et al. 1978; Cohen AH. et al. 1984). 
Furthermore, a positive correlation has been reported between uromodulin urinary excretion and 
eGFR. Reduced levels of uromodulin were observed in numerous conditions affecting kidney 
function and/or integrity, such as glomerulonephritis, diabetes nephropathy, lupus nephritis, 
tubulointerstitial nephropathy, and polycystic kidney disease. Of note, a shorter atypically 
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processed urinary uromodulin fragments were detected in Fabry disease patients (Vyletal P. et al. 
2008; Vyletal P. et al. 2010). 
3.3.2 Complex disorders: In addition to its direct involvement in ADTKD-UMOD, recent 
GWAS pointed at uromodulin as a risk factor for CKD, kidney stones, and hypertension 
(Rampoldi L. et al. 2011). Lately, Köttgen et al. have carried out an influential work on UMOD 
that contributed to redraw the attention of scientists to this protein. In her GWAS, performed in a 
population-based cohort, mainly of European ancestry, Köttgen et al. reported a single nucleotide 
polymorphism (SNP) mapping within the promoter region of UMOD gene that is associated with 
eGFR and increased risk for CKD (Köttgen A. et al. 2010). The minor allele T of the identified 
SNP rs12917707 (G/T) confers 20 % reduction in CKD risk and elevated eGFR. The reported 
results were independent of known risk factor for renal disease (presence of hypertension or 
diabetes). This outcome was validated in large European cohorts, Icelandic population, Africans, 
East Asians as well as in European isolates (Chambers JC. et al. 2010; Pattaro C. et al. 2012; 
Sveinbjornsson G. et al. 2014; Liu CT. et al. 2011; Okada Y. et al. 2012). Replication studies 
revealed additional association between a second UMOD variant rs4293393 (located in the 
promoter region of UMOD gene and in full linkage disequilibrium (LD) with rs12917707) and 
risk for CKD and kidney function (Gudbjartsson DF. et al. 2010). Furthermore, a third SNP, 
rs13333226, located in the UMOD promoter within the previously mention LD block was 
described to be associated with higher predisposition to hypertension and cardiovascular disease 
in a large European case-control study (Padmanabhan S. et al. 2010). The common variant 
rs13333226 had the minor allele G associated with a protective effect for CKD and renal 
function. Further studies have reported a genetic association of UMOD promoter gene variants 
with end-stage renal disease, type 2 diabetic nephropathy, uric acid levels and increased risk of 
gout (Böger CA. et al. 2011; Ahluwalia TS. et al. 2011; Han J. et al. 2013). Only in the case of 
renal stones, UMOD SNPs held a protective role contrary to the rest of diseases. Köttgen et al. 
tried to find out the functional contribution of UMOD variants to the risk of developing CKD by 
conducting a case-control study of incident CKD. The study results indicated that UMOD 
variants exert a direct effect on UMOD urinary excretion that could cause progression of CKD 
and hypertension. Individuals carrying UMOD risk variants had significantly higher UMOD 
urinary levels in a dose-dependent manner (Köttgen A. et al. 2010). Adopting the GWA 
approach Olden et al. corroborate the role of UMOD variants in modulating UMOD excretion in 
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a large meta-analysis on more than 10000 individuals of European descent from three genetic 
isolates and three urban cohorts (Olden M. et al. 2014). The risk allele for CKD previously 
identified by Köttgen et al. was associated with higher UMOD levels and lower eGFR in the 
CKD Gen Consortium participants, in all six cohorts analyzed. The biological aspect of UMOD 
association has been disclosed in a recent work by Trudu et al. Using a transgenic mouse model 
that overexpresses UMOD (in comparison to the control) the authors documented an 
upregulation in UMOD gene expression when risk variants were present (in vivo and in vitro 
data). These results were evidenced at the protein levels in large cohorts. Over-expressing 
UMOD in Umod transgenic mice resulted in salt-sensitive hypertension suggesting a cause-effect 
relationship between UMOD risk variants and increased blood pressure (BP). This consequence 
is mainly triggered by the over-activation of the TAL NKCC2. This process is implicated in 
human hypertension, as BP was reduced after administering furosemide only in hypertensive 
participants homozygous for UMOD risk variants (Trudu M. et al. 2013). Graham et al.’s work 
also highlighted the role of UMOD in regulating BP by showing that UMOD deficient mice have 
lower baseline BP that is not increased by high-salt diet, in contrast to control mice (Graham LA. 
et al. 2014). This observation is coherent and corresponds to the one described in Umod-
overexpressing mice, associating UMOD expression, salt intake and BP regulation. 
 
Taken together, these studies contribute to understand the role of UMOD suggesting that 
this ‘old’ molecule retains several fundamental roles in the kidney and modifications affecting its 
levels and structure might cause common diseases as hypertension and CKD. Besides the 
variants in the UMOD, candidate-based analysis revealed some genes expressed in the TAL 
harbouring variants that might influence the excretion of uromodulin in the urine such as KCNJ1 
(encoding ROMK), SORL1 and CAB39 proposing the existence of a regulatory networks that 
needs to be characterized through further investigation (Olden M. et al. 2014). More studies are 
needed to elucidate the role of UMOD in hypertension, CKD and possibly other common human 
diseases (e.g. UTI, nephrolithiasis) also to gain further insight into its complex biological 
functions and factors influencing its urinary excretion and interactions in the epithelial cells 
lining the TAL in the human kidney. 
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4. Urine osmolarity  
 
Urine osmolarity is a useful biomarker that reflects the concentrating ability of the nephron, 
which itself plays a crucial role in regulating water and sodium excretion. Diluted urine is 
produced in case of increased water intake whereas urine more concentrated than blood is 
produced when water intake is decreased. In both cases, urinary sodium excretion and the total 
urinary solute excretion rate vary within narrow ranges. In contrast to solute excretion, urine 
osmolality varies widely in response to changes in water intake (Sands J. et al. 2009). Changes in 
urine osmolarity are affected by several factors of which the antidiuretic hormone vasopressin 
(ADH or AVP) that acts on the distal convoluted tubule and the principal cells of the collecting 
duct. In addition to its association with water disorders, it has been shown that AVP is 
significantly associated with the incidence or progression of diseases such CKD, ADPKD, 
diabetic nephropathy, obesity, metabolic syndrome, and insulin resistance (Devuyst O. et al. 
2013; Bardoux P. et al. 2013; Enhorning S. et al. 2011; Roussel R. et al. 2011; Ho TA. et al. 
2012; Ponte B. et al. 2015). Therefore, studying AVP and its effects has become of significant 
importance. However, measuring circulating levels of AVP is challenging because of its small 
mass, very low circulating concentrations, poor stability in vitro, and time-consuming assays. For 
this purpose, the majority of current studies use copeptin (surrogate of AVP) or urine osmolarity, 
which reflects the action of AVP on distal tubular segments of the kidney (Clark WF. et al. 2011; 
Strippoli GF. et al. 2011). Considering the technical constraints in measuring urine osmolarity, 
surrogates of this parameter have been suggested using different equations that are based on the 
urinary levels of sodium and other components that are easily measurable. These surrogates lack 
validation in in the general population. 
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II. Aim of the thesis 
 
Despite its discovery more than 50 years ago, little is known about the function of uromodulin, 
the most abundant protein in normal human urine. 
The aim of this thesis was (1) to develop and characterize an assay to accurately measure the 
levels of uromodulin in the urine and to use this assay to (2) investigate the effect of a common 
variant in the promoter region of UMOD gene on the biochemistry of this glycoprotein and its 
circulating levels. We (3) employed our assay to determine the clinical and biological factors 
influencing the levels of uromodulin in urine. 
In the first part of this thesis, we developed an ELISA to measure uromodulin in human urine. 
We used this assay to explore the stability of uromodulin under different treatments and storage 
conditions. We then characterized the conditions of sampling and storage necessary to provide a 
faithful dosage of uromodulin in the urine in large cohorts. 
In the second part of the thesis, we explored the potential impact of a common promoter variant 
of UMOD on urine and plasma level and on biochemical properties of uromodulin by measuring 
uromodulin levels in two Swiss urban cohorts. 
In the third part, we studied the influence of clinical, biological and genetic factors on the 
uromodulin levels, based on several large cohorts. 
In the final part, we validated two formulas as surrogates for urine osmolarity, an integrative 
biomarker of kidney function, in the general population as well as in chronic kidney disease 
patients. 
Taken together, our results presented a reliable tool and consistent procedure allowing an 
accurate measurement of uromodulin in the urine. We also evidenced factors that affect the 
biochemistry and the excretion levels of uromodulin in urine and plasma. Finally, we validated 
uromodulin as a biomarker for tubular mass and function in the general population. 
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Abstract  
 
Uromodulin (Tamm-Horsfall protein) is the most abundant protein excreted in the urine under 
physiological conditions. It is exclusively produced in the kidney and secreted into the urine via 
proteolytic cleavage. The involvement of UMOD, the gene that encodes uromodulin, in rare 
autosomal dominant diseases, and its robust genome-wide association with the risk of chronic 
kidney disease suggest that the level of uromodulin in urine could represent a critical biomarker 
for kidney function. The structure of uromodulin is complex, with multiple disulfide bonds and 
typical domains of extracellular proteins. Thus far, the conditions influencing stability and 
measurement of uromodulin in human urine have not been systematically investigated, giving 
inconsistent results. In this study, we used a robust, in-house ELISA to characterize the 
conditions of sampling and storage necessary to provide a faithful dosage of uromodulin in the 
urine. The levels of uromodulin in human urine were significantly affected by centrifugation and 
vortexing, as well as by the conditions and duration of storage. These results validate a simple, 
low-cost ELISA and document the optimal conditions of processing and storage for measuring 
uromodulin in human urine.  
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Introduction 
 
Urinary biomarkers constitute an essential tool for the diagnosis, classification, and prognosis of 
kidney diseases (Koyner JL. et al. 2010). Recent evidence pointed at uromodulin (originally 
named Tamm-Horsfall glycoprotein) as a potential urinary biomarker relevant for renal function, 
chronic kidney disease (CKD) and hypertension (Tamm I. et al. 1950; Rampoldi L. et al. 2011). 
Uromodulin is a 105 kD glycoprotein with seven N-glycosylation sites and a high-mannose 
chain. The protein contains 616 amino acids including 48 cysteine residues that are all engaged 
in the formation of disulfide bonds. Uromodulin contains three epidermal growth factor (EGF)-
like domains and a zona pellucida (ZP) domain, found in many extracellular proteins, as well as 
a glycosylphosphatidylinositol (GPI)-anchoring site (Rampoldi L. et al. 2011). Uromodulin is a 
kidney-specific protein that is exclusively synthesized in the epithelial cells lining the thick 
ascending limb (TAL) of Henle’s loop (Chabardès-Garonne D. et al. 2003). After proper 
trafficking and maturation in TAL-lining cells, uromodulin reaches the apical plasma membrane, 
to be cleaved and assembled in the urine as polymers forming a gel-like structure (Wiggins RC. 
et al. 1987). 
Uromodulin is produced at very high rate in the TAL, and is by far the most abundant 
protein in normal urine (excretion: 50-100 mg/day) (Serafini-Cessi F. et al. 2003). Functions 
attributed to uromodulin include protection against urinary tract infections; prevention of renal 
calculi formation by reducing aggregation of calcium crystals and influencing transport 
processes by regulating the activity of NKCC2 and/or ROMK (Renigunta A. et al. 2011; Mutig 
K. et al. 2011). Interest for uromodulin was re-ignited when it was discovered that mutations in 
the UMOD gene that codes for uromodulin are responsible for a series of monogenic disorders 
(familial juvenile hyperuricemic nephropathy, medullary cystic kidney disease type 2 or 
glomerulocystic kidney disease) all known as uromodulin-associated kidney disease (UAKD) 
(Rampoldi L. et al. 2011). These disorders are characterized by severe tubulointerstitial damage, 
defective urinary concentration, hyperuricemia and gout, and progressive renal failure (Bollée G. 
et al. 2011). The mutations often affect cysteine residues, resulting in conformational changes 
and intracellular aggregates of uromodulin. In turn, there is a strong decrease in the secretion of 
the protein by the TAL cells and a strong decrease in the urinary excretion of uromodulin (Dahan 
K. et al. 2003; Bleyer AJ. et al. 2004; Bernascone I. et al. 2010). Lately, a number of genome 
wide association studies (GWAS) revealed that variants in the UMOD gene were strongly 
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associated with markers of renal function and risk of developing hypertension and CKD in the 
general population (Padmanabhan S. et al. 2010; Köttgen A. et al. 2009; Chambers JC. et al. 
2010). The association of uromodulin with both monogenic diseases and complex disorders such 
as CKD and hypertension provides a strong rationale for evaluating its urinary concentration as a 
biomarker for renal function and CKD. 
The determination of uromodulin in the urine is hampered primarily by its capacity to 
aggregate and the potential instability of such a complex protein. Documentation of sampling, 
processing and storage conditions is thus crucial for accurate uromodulin quantification. Despite 
the early characterization of antibodies specific for human uromodulin (Brunisholz M. et al. 
1986), the few reports on uromodulin dosage yielded conflicting results in terms of stability, 
storage conditions and processing of human urine (Akesson I. et al. 1978; Uto I. et al. 1992; 
Torffvit O. et al. 1992; Kobayashi K. et al. 2001). Important points such as the potential 
influence of urine centrifugation or vortexing, acidification or alkalinization, treatment with 
protease inhibitors or normalization for urinary creatinine remain unsolved. Furthermore, earlier 
immunoassays were often based on poorly documented anti-uromodulin antibodies. Considering 
the increasing interest for a robust determination of uromodulin in the urine, the need for a high-
throughput assay and the limited and contradictory information available, we developed and 
characterized a robust ELISA for uromodulin and used this assay to investigate the stability of 
uromodulin under different treatment and storage conditions of human urine. 
Material and Methods 
 
Urine sample collection, storage and handling 
Analyses were performed on second morning urine samples collected (mid-stream) in a sterile 
container from healthy volunteers aged 18-50 years, and processed within 2 h. This protocol was 
approved by the Ethical Committee of the Université catholique de Louvain. 
The influence of human urine sample processing on the determination of uromodulin 
(Figure 1) was tested after vortexing the sample for 10 sec (Vortex-Genie 2, FAUST, 
Schaffhausen, Switzerland); centrifugation for 10 min at 3,600 rpm (Eppendorf Centrifuge 5430, 
Hamburg, Germany) at room temperature (i.e. standard protocol for urine processing and 
removing cells and debris; Thomas CE. et al. 2010); treatment with protease inhibitors 
(Leupeptin 1 µmol/L; Sigma-Aldrich, St. Gallen, Switzerland; sodium azide 10 mmol/L); pH 
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adjustment performed by drop titration with 1 N HCl (to pH 2.0) or with 1 N NaOH (to pH 8.0) 
using a Hanna HI 2211 pH meter; dilution using ultrapure deionized water (Destamat Bi 18E, 
QCS, Maintal, Germany) vs. TEA buffer (0.5 % Triton X-100, 20 mM EDTA, pH 7.5). 
 
 
 
Figure 1: Processing of urine samples for uromodulin determination. The flow chart describes how urine 
samples were collected and treated to validate the protocol of uromodulin determination. Grey boxes 
represent the standard treatment to measure uromodulin in the urine 
 
The effect of storage conditions was tested by comparing baseline levels with 1-week and 5-
month storage at room temperature, +4 °C and -20 °C; 4-month and 8-month storage at -80 °C; 
five cycles of freezing-thawing (sample kept at -80 °C for 48 h followed by thawing on ice). 
Different sample sets were used to evaluate the influence of the various processing conditions as 
described. 
Uromodulin ELISA 
The in-house ELISA for uromodulin is a colorimetric based sandwich immunoassay using a 
sheep anti-human uromodulin antibody (Meridian Life Science, Memphis, USA; K90071C) as 
the capture antibody. This antibody gives a single arc when tested by immuno-electrophoresis 
against fresh urine. The primary antibody was a monoclonal anti-human uromodulin antibody 
(Cedarlane Laboratories, Burlington, USA; CL 1032A) raised in mouse and validated in solid 
phase radioimmunoassay. The secondary antibody was a goat anti-mouse IgG (H+L) horseradish 
42  
 
peroxidase conjugated (Bio-Rad, Cressier, Switzerland; 172.1011). The substrate was O-
Phenylenediamine dihydrochloride (OPD) (10 mg/tablet) (Sigma-Aldrich). The OPD substrate 
solution was freshly prepared by dissolving a tablet in 25 mL of phosphate-citrate buffer (0.1 M 
citric acid monohydrate, 0.2 M Na2HPO4), pH 5.5. A volume of 5 µL 30 % H2O2 was added to 
25 mL of substrate solution. Human uromodulin (Millipore, Billerica, USA) was used to 
establish the standard curve, with freshly prepared serial dilutions from the standard stock 
solution (100 µg/mL). Both the standard curve and a standard sample (uromodulin concentration 
25 µg/mL) were systematically used for quality control (QC). The determination of urinary 
uromodulin by ELISA was carried out as follows: a 96-well microtiter plate (NUNC 
MaxiSorp™, eBioscience, Vienna, Austria) was coated with 100 µL of 5 µg/mL capture 
antibody in coating buffer (500 mM H3BO3, 500 mM KCl, 345 mM NaOH, pH 9.0). The plate 
covered with adhesive seal was incubated at 4 °C overnight then washed three times with freshly 
prepared washing buffer (0.1 % Tween 20 in 10 mM phosphate buffer saline (PBS) pH 7.2 
(PBS-Tween 0.1 %)) using ImmunoWash 1575 Microplate Washer (Bio-Rad). Unoccupied sites 
on the plate were blocked with 100 µL blocking buffer (0.5 % BSA in 10 mM PBS, pH 7.2) and 
incubated at 37 °C for 1 h with a slow rotation (100 rpm). The plate was then washed three times 
with washing buffer and placed upside-down on absorbent paper to remove residual buffer. 100 
mL of PBS-Tween 0.1 % was dispensed in all wells. Urine samples were stabilized at room 
temperature then diluted 1:50 in ultrapure deionized water, as preliminary testing revealed no 
significant difference vs. dilution with TEA buffer (data not shown). A volume of 100 µL per 
well was distributed into the coated wells after vortexing. Standards and QC sample were run in 
duplicate whereas each urine sample was tested in 3 different dilutions. Deionized water was 
used as blank. After 1 h incubation at 37 °C, the plate was washed three times and placed on 
absorbent paper. 100 µL of primary antibody diluted in PBS-Tween 0.1 % (1 µg/mL) was 
dispensed in each well; the plate was incubated at 37 °C for 1 h (rotation, 100 rpm) then washed 
three times. The secondary antibody diluted 1: 2,000 in PBS-Tween 0.1 % was added to the 
wells for 45 min at 37 °C and the plate washed three times. Colour was developed by adding 100 
µL of OPD substrate solution. The plate was incubated at room temperature in the dark for 1 
min, and the reaction stopped by adding 50 µL of 2 M H2SO4 to each well. Optical density 
(Infinite M200Pro, Tecan; Grödig, Austria) was read at 492 nm and urinary uromodulin 
concentration was determined by referring to the standard curve. Uromodulin levels obtained 
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using the in-house ELISA were compared to the commercial ELISA from MD Bioproduct (St. 
Paul, USA; M036020), following the protocol given by the manufacturer. This test has been used 
in several studies (Padmanabhan S. et al. 2010, Reznichenko A. et al. 2011). Urinary creatinine 
levels (normalization) were measured using the Synchron® System Creatinine Assay (Unicell 
DxC Synchron®, Beckman Coulter, Brea, USA), following the manufacturer’s instructions. 
Immunoblotting 
Kidneys from Umod mice (Mo L. et al. 2004) were grounded in liquid nitrogen and 
homogenized as described previously (Bernascone I. et al. 2010). The homogenate was 
centrifuged at 1000 × g for 15 min at 4 °C and the resulting supernatant at 100,000 × g for 120 
min at 4 °C. The pellet was suspended in homogenization buffer before determination of protein 
concentration (Pierce BCA protein assay kit; Thermo Fischer Scientific; Rockford, USA). SDS-
PAGE for mouse and human samples was performed under reducing conditions. Samples (20 µg 
of mouse and human kidney extract; 2 µL of urine) were loaded after being mixed with Laemmli 
sample buffer and heated for 5 min at 95 °C (kidney samples). Proteins were separated on 10 % 
SDS gel and transferred to nitrocellulose membrane for Western blotting. Membranes were 
blocked with 5 % milk blot for 30 min at room temperature then incubated overnight at 4 °C 
with either sheep or mouse anti-uromodulin antibodies (1:400 in 0.5 % BSA blocking buffer). 
Secondary antibodies were goat anti-mouse HPR conjugated (1:10,000) or polyclonal rabbit anti-
sheep HRP conjugated (1:1,000), for 1 h at room temperature. Antigen-antibody reaction was 
detected by using ECL (Immun-Star HRP, Bio-Rad) and light-sensitive film (GE Healthcare, 
Glattbrugg, Switzerland). The molecular weight was estimated by running the Precision Plus 
Protein™ All Blue standard (Bio-Rad). 
Deglycosylation and desialylation of uromodulin 
Deglycosylation of uromodulin from human urine was carried out using PNGase F (PNGase F 
P0704S, New England Biolabs, Ipswich, USA) following the manufacturer’s protocol, whereas 
desialylation was performed according to the protocol described by Parsons et al. (Parsons CL. et 
al. 2007). Briefly, uromodulin was precipitated from pooled human urine (1.5 L) following the 
protocol of Tamm and Horsfall (Tamm I. et al. 1950), dialyzed overnight at 4 ˚C and then 
lyophilized (Virtis, Kloten Switzerland). Dry uromodulin was solubilized in 2.5 M acetic acid 
(10 mg/ml), heated for 3 h at 82 °C, and then washed 3 times with 15 mL PBS (pH 7.2) on 
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Centricon (MWCO 30000) cartridge (Millipore). 1.5 µL of deglycosylated urine and 0.1 µL of 
desialylated uromodulin (vs. 0.5 L of untreated urine) were loaded on 10 % acrylamide gel and 
analyzed as described above. 
Immunohistochemistry  
Colocalization of uromodulin with NKCC2 was carried out in cryosections of human and mouse 
kidney samples as previously described (Dahan K. et al. 2010; Bernascone I. et al. 2003). 
Briefly, 5 µm-thick cryosections were blocked with 1 % BSA, 0.02 % sodium azide-PBS for 30 
min at room temperature, incubated for 2 h at room temperature with the sheep (1:400) or mouse 
(1:200) antibodies against human uromodulin, followed by washing and incubation with 
AlexaFluor633-conjugated donkey anti-sheep or goat anti-mouse (1:200) for 90 min at room 
temperature. Uromodulin-stained sections were then incubated with a polyclonal rabbit anti-
NKCC2 antibody (Millipore; AB3562P; 1:100) for 3 h at room temperature, followed by 
washing and incubation with Alexafluor488-conjugated goat anti-rabbit antibodies (1:200). 
Sections were viewed on a Leica SP5 confocal microscope. 
Surface plasmon resonance: Biacore 
The interaction between uromodulin and the capture antibody was analyzed by surface plasmon 
resonance, using a Biacore T100 system (GE Healthcare, Uppsala, Sweden). Chemicals were 
from Sigma unless otherwise noticed. Binding experiments were performed in PBS buffer pH 
7.4 containing 0.2 % of Tween 20 at a flow rate of 30 µL/min at 25 °C. Ultrapure and filtered 
water (“MilliQ”, Millipore, Billerica, USA) was used for preparing all solutions. The 
carboxymethyl dextran chip (CMD500L, XanTec bioanalytics, Düsseldorf, Germany) surface 
(1.2 mm2 area) was cleaned before use by injecting 7 times a 50 mM NaOH solution containing 
1 M NaCl for 30 sec at a flow rate of 5 µL/min. Surface binding is expressed in terms of changes 
in response units (RU) with 1 RU being approximately 1 pg/mm2. Sheep polyclonal anti-
uromodulin antibody (300 nM) in PBS-Tween was immobilized by amine coupling to the chip 
surface activated with aqueous solutions of 0.4 M 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide and 0.1 M N-hydroxysuccinimide for 300 sec at 5 µL/min flow rate. For 
determination of kinetic constants, a dilution series of four concentrations (19 nM, 39 nM, 78 
nM, 156 nM) of uromodulin was injected using the T100 in multichannel mode. The reference 
channel used in parallel did not contain immobilized antibody, in order to detect background 
response and unspecific binding of analyte to the surface. Between two measurements, the 
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surface was regenerated by injecting twice 10 mM glycine at pH 2 for 30 sec, which completely 
removed uromodulin from the antibody. For data evaluation, the measured sensorgrams were 
referenced twice, first by subtracting the signal from the reference channel, and second by 
subtracting the signal obtained from injected pure buffer solution. Kinetic curves were evaluated 
using Biacore T100 Evaluation Software (v. 2.0.2). A global fit was performed using the entire 
concentration series. Rate constants for association and dissociation were calculated by taking a 
1:1 binding model as a basis. 
Data analysis 
Data were analyzed using Statistical Package for Social Sciences (SPSS) version 19 (IBM Corp., 
Armonk, USA). The Pearson correlation coefficient was used for correlation analysis, whereas 
ANOVA and paired t-test were used for comparisons between the groups. A Bland-Altman plot 
was used to evaluate agreement between uromodulin levels measured with the in-house ELISA 
and commercial kit. Level of significance was set to p < 0.05.  
Results 
 
Characterization of the antibodies against human uromodulin 
The antibodies used for the in-house ELISA were characterized by immunoblotting and 
immunostaining (Figure 2). Immunoblot analysis of human urine and kidney samples in parallel 
with mouse kidney samples using the sheep polyclonal antibodies detected the uromodulin band 
at ~100 kDa in all samples except the Umod KO kidney sample. The uromodulin band was also 
detected in human urine and kidney samples using the mouse monoclonal antibody (Figure 2A, 
top panel). 
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Figure 2A (Top panel): Characterization of anti-human uromodulin antibodies. Western blot analysis (10 
% acrylamide gel) of human urine (2 µL), human kidney tissue (20 µg), and Umod knock-out (KO) and 
wild-type (WT) mouse kidney tissue (20 µg) using the sheep polyclonal or the mouse monoclonal 
antibodies against human uromodulin. A single band at ~100 kDa is detected with both antibodies, and 
absent in the Umod KO mouse kidney. Figure 2A (Lower panel): Characterization of anti-human 
uromodulin antibodies. The changes in molecular mass resulting from deglycosylation (left panel) and 
desialylation (right panel) of uromodulin are evidenced by using both the polyclonal and monoclonal anti-
uromodulin antibodies. 1.5 µL of deglycosylated urine and 0.1 µL of desialylated uromodulin (vs. 0.5 L of 
untreated urine) were loaded on the gel. 
 
Both the polyclonal and monoclonal antibodies also appropriately identified the deglycosylated 
and desialylated forms of uromodulin (Figure 2A, lower panels). 
Staining of human and mouse kidney tissue samples with the mouse monoclonal or the sheep 
polyclonal antibodies detected uromodulin in the TAL, where it colocalized with NKCC2 at the 
apical surface area (Figure 2B). 
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Figure 2B: Characterization of anti-human uromodulin antibodies. Immunostaining of human cortical 
kidney sections (top row) using polyclonal sheep antibodies against human uromodulin (red), evidencing 
the apical staining in thick ascending limb profiles that are also positive for NKCC2 (green). A similar co-
distribution between uromodulin (red) and NKCC2 (green) is observed in mouse kidney, using the 
polyclonal (middle row) or monoclonal (bottom row) anti-uromodulin antibodies. Scale bar: 10 µm, inset: 
2x zoom. 
 
Surface plasmon resonance (van der Merwe PA. 2001) was further used to characterize the 
uromodulin-antibody interaction (Figure 2C). 
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Figure 2C: Characterization of anti-human uromodulin antibodies. Sensorgrams for the interaction of 
purified human uromodulin (19 - 156 nM) with the immobilized sheep anti-uromodulin antibody by surface 
plasmon resonance technique using the Biacore system. Uromodulin was injected at 0 for 300 sec. Red 
lines are the result of a global fit. The constant of dissociation (KD) was determined after evaluating the 
association (kon) and dissociation (koff) rate constants simultaneously using 1:1 kinetic binding model. 
 
As the isoelectric point of uromodulin (pI = 3.2) is too low for its immobilization to a 
carboxymethyl dextran surface, the capture sheep anti-uromodulin antibodies were immobilized 
at the surface of a sensor chip, and a dilution series of uromodulin was injected. For the 
interaction of immobilized sheep anti-uromodulin antibody with uromodulin, rate constants for 
association (kon) and dissociation (koff) of 4 x 104 M-1 s-1 and 4 x 10-4 s-1, respectively, were 
determined, giving a dissociation constant KD (= koff/kon) of 10 nM. We also measured a strong 
binding response for the interaction of mouse anti-human uromodulin antibody to the sheep anti-
uromodulin antibody - uromodulin complex. This situation is comparable to the conditions in 
ELISA (see below). Regeneration of the surface with 10 mM glycine at pH 2.0 removed both the 
antibody and uromodulin. 
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Table 1: Comparison of the characteristics of the in-house ELISA for uromodulin and the available 
commercial ELISA kits. 
 
Characteristics of the ELISA for uromodulin 
When tested against purified human uromodulin, the in-house ELISA for human uromodulin 
showed a sensitivity (minimum amount of analyte which can be accurately detected) of 2.8 
ng/mL and a linearity (correlation between concentration and optical density) of 1.0 (Figure 3A). 
The inter- and intra-assay variabilities were determined at 3.28 % and 5.46 %, respectively. The 
assay had a detection range between 3.9 and 500 ng/mL. When compared with other assays, the 
in-house ELISA showed a wider range of measurement and lower intra- and inter-assay 
variability than commercially available routine kits (Table 1). 
 
Kit 
Detection range 
(standard curve) 
Inter-assay 
Variability 
Intra-assay 
Variability 
In-house 3.9 - 500 ng/mL 3.28 % 5.46 % 
MD Bioproduct 
(Cat. M036020) 
2.34 - 150 ng/mL 11.63 % 8.36 % 
BioVendor 
(Cat. RD191163200R) 
0.5 - 32 ng/mL 6.4 % 2 % 
USCN Life Science Inc. 
(Cat. E96918 Hu) 
3.13 - 200 ng/mL < 12 % < 10 % 
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Figure 3A: Characterization of the in-house ELISA for uromodulin. Standard curve of absorbance for a 
dilution series (500, 250, 125, 68, 34, 17, 8.5 and 3.9 ng/mL) of purified human uromodulin. 
 
There was a robust correlation (r = 0.905, p < 0.001) when comparing the in-house ELISA with 
the MD Bioproduct kit. The Bland-Altman plot showed that the mean difference between both 
methods was -1.47 µg/mL (95 % CI, -3.21 to 0.27 µg/mL) (Figure 3B). 
 
 
 
Figure 3B: Characterization of the in-house ELISA for uromodulin. Bland-Altman plot: The difference 
between uromodulin levels measured with in-house ELISA and the commercial kit plotted against mean 
uromodulin levels measured with both methods (n = 28). Horizontal lines represent the mean difference for 
the whole group (-1.47 g/mL) and the 95 % limits of agreement (-10.40 g/mL to 7.45 g/mL). 
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Influence of processing of urine samples 
Since uromodulin has a tendency to aggregate, we first investigated the potential influence of 
vortexing and centrifugation on the determination of uromodulin levels in human urine (Table 2). 
  
Unindexed 
Uromodulin 
(µg/mL) 
 
 
P 
Indexed 
Uromodulin 
(mg/gr creat) 
 
 
P 
 
 
N 
Vortex 11.03 ± 1.67 
0.001 
15.90 ± 1.45 
0.001 37   
 
No vortex 5.02 ± 0.66 10.84 ± 0.54 
Centrifugation 
 
6.40 ± 0.63 
 
 
< 0.001 
9.97 ± 1.43  
  
 
< 0.001 
 
53 
No centrifugation 13.27 ± 1.18  15.66 ± 1.34   
        
Table 2: Effect of sample processing (vortex, centrifugation) on the concentration of uromodulin in the 
urine. Urine samples were vortexed for 10 s. Centrifugation was performed for 10 min at 3600 rpm at 
room temperature. Two different sets of samples were used to test the influence of vortexing (N = 37) and 
centrifugation (N = 53). 
 
Comparison of fresh samples assayed before and after vortexing revealed a more than 50 % 
increase in uromodulin levels (unindexed uromodulin: 5.02 ± 0.66 vs. 11.03 ± 1.67 g/mL, 
respectively, p = 0.001; indexed uromodulin: 10.84 ± 0.54 vs. 15.90 ± 1.45 mg/gr creat, 
respectively, p = 0.001, n = 37). Treating the urine samples with an usual centrifugation protocol 
(10 min, 3600 rpm) also showed a strong effect, since centrifugation yielded a significant 
decrease in unindexed (6.40 ± 0.63 vs. 13.27 ± 1.18 g/mL, respectively, p < 0.001) and indexed 
(9.97 ± 1.43 vs. 15.66 ± 1.34 mg/gr creat, respectively, p < 0.001, n = 53) uromodulin levels. 
Immunoblotting analyses (Figure 4) revealed that centrifugation was responsible for the 
precipitation of uromodulin in the pellet of cell debris. 
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Figure 4: Effect of urine centrifugation on the detection of uromodulin. Western blot analysis (10 % 
acrylamide gel) of two human urine samples (S1, S2) using the polyclonal sheep anti-uromodulin antibody. 
The signal obtained in baseline urine is lost when analyzing the supernatant following centrifugation, 
whereas a clear signal appears in the pellet. Similar volumes (2 L) of untreated urine, supernatant and re 
suspended pellet were loaded. 
 
In comparison with the uromodulin band detected in fresh, non-centrifuged urine samples, the 
signal was strongly attenuated in the centrifuged urine sample while becoming apparent in the 
resulting pellet. 
Alkalinization of fresh urine sample to pH 8.0 did not influence the determination of urinary 
uromodulin, as compared with untreated (mean pH 5.68 ± 0.19) samples (unindexed uromodulin: 
19.25 ± 4.14 vs. 20.60 ± 5.24 g/mL, respectively, p = 0.179; indexed uromodulin: 17.56 ± 2.28 
vs. 18.34 ± 2.67 mg/g creat, respectively, p = 0.260, n = 14). Likewise, acidification of urine 
samples to pH 2.0 did not result in a significant difference between values from untreated (mean 
pH 6.15 ± 0.59) samples (unindexed uromodulin: 10.01 ± 2.25 vs. 9.73 ± 2.07 μg/mL, 
respectively, p = 0.621; indexed uromodulin: 18.86 ± 8.26 vs. 19.10 ± 8.55 mg/g creat, 
respectively, p = 0.782, n = 8). 
 
Influence of storage conditions 
In order to cast light on the influence of storage conditions on the stability of uromodulin, we 
compared values obtained in samples analyzed at baseline and after 1 week or 5 months storage 
at room temperature, +4 °C and -20 °C. As compared to baseline, storage at either room 
temperature or 4 °C or even -20 °C were associated with decreased levels of both unindexed and 
indexed uromodulin (Table 3). 
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Unindexed 
Uromodulin 
(µg/mL) 
P 
Indexed 
Uromodulin 
(mg/g creat) 
 
P 
 
N 
1 week 
storage 
Baseline 12.39 ± 2.41  22.70 ± 3.35   
RT 6.14 ± 1.34* 
0.078# 
13.00 ± 2.34* 
0.014# 13 +4 °C 7.22 ± 1.60* 11.49 ± 1.50* 
-20 °C 9.98 ± 1.96* 18.69 ± 3.18* 
4 month 
storage 
Baseline 36.37 ± 2.62 0.354 
24.05 ± 1.26 
0.412 61 
-80 °C 35.47 ± 2.32 23.30 ± 1.25 
5 month 
storage 
Baseline 28.50 ± 6.76  
 
0.068# 
 
0.111# 
26.48 ± 3.45  
 
0.001# 
 
0.003# 
10 
+4 °C 10.17 ± 3.96*  10.27 ± 2.35* 
-20 °C 16.52 ± 5.08*  15.78 ± 2.73* 
+4 °C & PI 11.04 ± 4.69* 10.80 ± 2.32* 
-20 °C & PI 20.23 ± 5.27*£ 18.71 ± 2.69*£ 
 
Table 3: Effect of storage conditions (duration, temperature, protease inhibitors) on the concentration of 
uromodulin in the urine. PI, treatment with protease inhibitors (Leupeptin and sodium azide). Three 
different sets of urine samples were used to assess influence of storage after 1 week (N = 13), 4 months (N 
= 61) and 5 months (N = 10) vs. baseline levels. * p < 0.05 storage condition vs. baseline, £ p < 0.05 no vs. 
protease inhibitors, paired t tests; # ANOVA. 
 
Addition of protease inhibitors at the time of collection had some effect on the degradation of the 
samples conserved at -20 °C, but not on those kept at +4 °C. In any case, the addition of protease 
inhibitors was insufficient to prevent a significant decrease in the uromodulin levels as compared 
to baseline values. In contrast, 4-month storage at -80 °C was not associated with significant 
changes in uromodulin levels in untreated samples. Further analyses revealed a slight but 
significant decrease after 8 months storage at -80 °C (baseline uromodulin: 23.73 ± 1.57 µg/mL 
vs. 8-month: 20.13 ± 1.17 µg/mL, p = 0.023, n = 142). Freezing-thawing cycles (from -80 °C to 
0 °C) showed no significant changes in the levels of urinary uromodulin as compared to baseline 
(Table 4). 
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Unindexed 
Uromodulin 
(µg/mL) 
 
 
P 
Indexed 
Uromodulin 
(mg/gr creat) 
 
 
P 
 
 
N 
Freezing-
thawing 
cycles 
(-80 °C to 0 
°C) 
Baseline 22.96 ± 4.75 
0.616# 
18.14 ± 2.82 
0.351# 8 
1 22.01 ± 3.81 20.19 ± 3.51 
2 24.74 ± 4.05 23.67 ± 3.07 
3 16.74 ± 2.68 18.17 ± 2.58 
4 16.96 ± 3.36 16.20 ± 1.98 
5 19.42 ± 4.56 15.91 ± 2.42 
 
Table 4: Effect of freezing-thawing cycles on the concentration of uromodulin in the urine. 
# ANOVA 
 
Discussion 
 
Increasing evidence suggests that the level of uromodulin in urine could represent a useful 
biomarker for kidney function (Rampoldi L. et al. 2011; Köttgen A. et al. 2010). In this study, 
we validated an efficient and cost-effective immunoassay and characterized the conditions of 
sampling and storage necessary to provide a faithful dosage of uromodulin in human urine. The 
urinary uromodulin levels were significantly affected by centrifugation and vortexing, as well as 
by the conditions and duration of storage. 
To develop our in-house ELISA we used commercially available anti-uromodulin 
antibodies and validated their specificity in human and mouse kidney and urine samples. Both 
antibodies evidenced the ~100 kDa band corresponding to uromodulin on Western blot, either in 
native or deglycosylated/desialylated state. They also showed the typical distribution along with 
NKCC2 in the apical membrane of the TAL. We used plasmon surface resonance to determine 
the binding constant for interaction of the immobilized sheep anti-uromodulin antibody to 
uromodulin to 10 nM which is in the expected range for an antibody-protein interaction. The 
immunoassay standard curve showed linearity over a broad range of values, allowing the 
detection of uromodulin with high sensitivity and very low inter- and intra-assay variability. It 
must be noted that, in contrast with previous results based on immunoblotting (Kobayashi K. et 
al. 2001), dilution of the samples with deionized water yielded similar results as with TEA 
buffer. All these features, combined with an excellent correlation with the most used commercial 
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ELISA, substantiate the interest of our immunoassay with the advantage of low cost, wide range 
of detection, and low variability. 
Our analyses revealed a striking effect of vortexing and centrifugation on the 
determination of uromodulin in the urine. These two procedures yielded variations reaching 50 
% of the levels obtained on control, unprocessed samples (Table 2). These findings are clinically 
relevant, because low levels of urinary uromodulin have been suggested to be of diagnostic value 
in UAKD (Rampoldi L. et al. 2011; Bollée G. et al. 2011; Dahan K. et al. 2003; Bleyer AJ. et al. 
2004). The effect of vortexing confirms the importance of the aggregation of uromodulin 
molecules in the normal urine. Uromodulin is also known to cofractionate with exosomes 
(Hiemstra TF. et al. 2011), the recovery of which is increased by vortexing (Zhou H. et al. 2011). 
Uto et al. previously suggested that uromodulin may be trapped in cell debris or aggregated with 
crystals (Uto I. et al. 1991) after centrifugation protocols that are usual to remove contamination 
due to lysis or suspended cells (Waikar SS. et al. 2010). Our data confirm these findings and 
show that centrifugation of urine may decrease the level of uromodulin by ~30 %. Thawed urine 
samples should thus be vortexed but not centrifuged before assaying uromodulin. 
The question of the stability of uromodulin during different storage protocols is critical for 
analyzing large, multicentric cohorts. Previous studies based on small sample size yielded 
inconsistent conclusions about the influence of storage duration and temperature (Akesson I. et 
al. 1978; Uto I. et al. 1991; Torffvit O. et al. 1992; Kobayashi K. et al. 2001). Furthermore, these 
studies did not take into account normalization for urinary creatinine, which is usual for kidney 
biomarkers – at least in a stable situation (Waikar SS. et al. 2010; Ortiz A. et al. 2011). Our 
results, obtained on a large number of samples, reveal that short (1 week) and longer (5 months) 
storage at room temperature, 4 °C or -20 °C causes a significant decrease in indexed urinary 
uromodulin levels, largely due to decreased uromodulin. In contrast, 4-month storage at -80 °C is 
associated with marginal, non-significant decrease in the unindexed and indexed values. Of note, 
the decrease in unindexed uromodulin levels becomes significant after a 8-month storage at -80 
°C. The fact that storage of untreated urine samples at room temperature, 4 °C or -20 °C 
significantly decreases the level of uromodulin substantiates the observations of Kobayashi et al 
(Kobayashi K. et al. 2001). This effect is only partially attenuated with protease inhibitors, which 
show some effect for samples kept at -20 °C - but insufficient to prevent a significant 
degradation. Taken together, these data confirm the fact that urine samples should be stored at     
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-80 °C and analyzed within 3 months to give the most reliable measurements. Of note, up to 5 
freezing-thawing cycles on ice did not affect the stability of uromodulin stored at -80 °C. 
Previous studies also reported inconsistent results in terms of treatments (detergents or TEA 
buffer, alkalinization) supposed to solubilize aggregates of uromodulin in urine (Akesson I. et al. 
1978; Uto I. et al. 1991; Torffvit O. et al. 1992; Kobayashi K. et al. 2001; Dawney AB. et al. 
1982). Some of these treatments may interfere with the binding of uromodulin to the ELISA 
capture antibody (Uto I. et al. 1991). We verified here that dilution with deionized water gave 
similar results than with TEA, and that urine alkalinization (or acidification) had no effect on the 
determination of uromodulin. These data support the conclusion that dilution of the sample with 
water before the assay, combined with vortexing, is an efficient way of disaggregation (Dawney 
AB. et al. 1982). 
In summary, these data indicate that reliable uromodulin measurements can be obtained from 
untreated urine samples, provided they are immediately stored at -80 °C and assayed within 3 
months, with vortexing and dilution with water to prevent aggregation. This methodology will be 
useful for high-throughput analyses of uromodulin and its validation as a biomarker for renal 
function and risk of CKD. 
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Abstract 
 
Uromodulin is exclusively expressed in the kidney and is the most abundant protein in normal 
urine. Common variants located in the promoter of the UMOD gene encoding uromodulin are 
associated with the excretion of uromodulin, and with the risk of chronic kidney disease and 
hypertension. The potential impact of the UMOD variants on plasma level and on biochemical 
properties of uromodulin remains unknown. 
The potential influence of the UMOD promoter variant rs12917707 on the urine and plasma 
levels of uromodulin (ELISA) was analyzed in two Swiss urban cohorts (n = 6'076). Qualitative 
analyses were carried out by immunoblotting, 2D-gel electrophoresis and Matrix-Assisted Laser 
Desorption/Ionization Mass Spectrometry (MALDI-MS) on urine samples from age- and sex-
matched homozygous carriers of protective or risk UMOD variants 
The common, risk allele of rs12917707 was associated with higher urinary uromodulin levels 
irrespective of normalization to creatinine, and with higher plasma levels of uromodulin 
independent of age, gender and eGFR. The plasma levels of uromodulin were ~1000-fold lower 
than urine levels. The rs12917707 variant influenced the immunoreactivity of uromodulin, 
depending on N-glycosylation pattern. These differences were confirmed by 2D-gel 
electrophoresis and substantiated by distinct glycan compositions as observed in MALDI-MS.  
These data show that common variants in the UMOD promoter region exert a strong influence on 
the urine and plasma levels of uromodulin and are associated with significant biochemical 
modifications of the protein. These results provide insights into the regulation of uromodulin and 
its biological properties. 
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Introduction 
 
Uromodulin (Tamm-Horsfall protein) is the most abundant urinary protein under normal 
physiological conditions. This complex protein is exclusively produced by tubular cells in the 
thick ascending limb (TAL) of the loop of Henle, and is secreted into the urine at a rate of 50 - 
100 mg per day. Uromodulin, which belongs to the family of zona pellucida (ZP) proteins, 
contains 48 cysteine residues involved in the formation of 24 disulfide bonds (Rampoldi L. et al. 
2011) as well as 7 potential N-glycosylation sites and a C-terminal glycosylphosphatidylinositol 
anchor attachment. O-linked glycosylation of uromodulin has also been reported (Easton RL. et 
al. 2000), Uromodulin is encoded by the UMOD gene located on chromosome 16p12.3, under 
the control of a promoter whose proximal part is highly conserved in mammalian species (Zhu 
X. et al. 2002). 
The biological role of uromodulin remains elusive. The protein is cleaved and released 
from the apical membrane of the TAL cells into the urine, where it is assembled into large, 
polymeric fragments. Uromodulin interacts with many urine components in vitro, and 
investigations based on the Umod knock-out (KO) mouse models revealed that it may protect 
against urinary tract infections through binding to type I fimbriated Escherichia coli (Bates JM. 
et al. 2004) and inhibit the formation of kidney stones by reducing the aggregation of calcium 
oxalate crystals (Liu Y. et al. 2010). Recently, mutations in UMOD have been associated with 
autosomal dominant tubulointerstitial kidney disease (ADTKD-UMOD) (Eckardt KU. et al. 
2015), a rare condition characterized by hyperuricemia, alteration of urinary concentrating 
ability, and tubulointerstitial fibrosis leading invariably to chronic renal failure. Furthermore, 
genome wide association studies (GWAS) consistently reported a significant association between 
common variants located in the promoter region of UMOD (e.g. rs12917707 G > T or rs4293393 
T > C) and renal function parameters, risk of CKD, kidney stones and hypertension. Initial 
studies by Köttgen et al. suggested that the UMOD promoter variants may modulate uromodulin 
levels, with risk allele carriers showing significantly higher uromodulin levels in urine (Köttgen 
A. et al. 2010). The direct role of the UMOD promoter variants was demonstrated by Trudu et al. 
who showed that risk alleles were significantly associated with increased expression and 
transcription of UMOD gene, both in vivo and in vitro (Trudu M. et al. 2013). Of interest, these 
variants were shown to activate the NKCC2 cotransporter in the TAL, causing a salt-sensitive 
increase in blood pressure, and to cause progressive lesions in the kidney (Trudu M. et al. 2013). 
64  
 
In a meta-GWAS encompassing 10,884 European subjects, Olden et al. showed a major effect of 
the UMOD promoter variants on the urinary levels of uromodulin (Olden M. et al. 2014). If the 
regulatory effect of UMOD promoter variants on the transcription and urinary levels of 
uromodulin is well established, the potential influence of these variants on the biochemical 
features of uromodulin and on its circulating levels are unknown. These questions are important, 
when considering that the lead UMOD promoter variants regulating uromodulin expression are 
located in a large LD block comprising exons 3, 4, and 6, containing the N-glycosylation sites. 
Possibly, genotype-related changes in glycosylation patterns may affect the interactions of 
uromodulin with uropathogenic Escherichia coli (E. coli.) Despite recent evidence linking urine 
uromodulin levels with systemic inflammation, potential correlations between urine and 
circulatory levels of uromodulin have not been investigated (Ghirotto S. et al. 2016).  
 
In this study, we investigated the potential impact of a common promoter variant of 
UMOD on urine and plasma level and on biochemical properties of uromodulin in two Swiss 
urban cohorts. Qualitative analyses were carried out to substantiate biochemical modifications of 
uromodulin obtained from homozygous carriers of protective or risk UMOD variants. 
Material and Methods 
 
Urine and plasma samples: The effect of UMOD genotype on urine uromodulin levels were 
analyzed in spot urine samples from the Swiss cohort CoLaus (n = 5'126). The CoLaus Study is a 
population-based cross-sectional study of more than 5000 participants (52.5 % women) aged 35-
75 years living in Lausanne, Switzerland. Clinical and biological data were collected on each 
participant including spot urine after an overnight fast (Firmann M. et al. 2008). The uromodulin 
immunoreactivity and the pattern of N-glycans with regards to UMOD genotype were analyzed 
in a subset of CoLaus samples selected for the rs12917707 genotype and matched for age, gender 
and creatinine-based estimated glomerular filtration rate (eGFR) eGFR was calculated with the 
CKD-Epidemiology Collaboration (CKD-EPI). The comparison between plasma and urine 
uromodulin levels was performed on samples from the Swiss kidney Project on Genes and 
Hypertension (SKIPOGH). In this family-based multi-centre cross-sectional study clinical and 
biological information were collected on participants including 24 h urine (day-time urine and 
night-time urine were collected in separate containers) and plasma (Ponte B. et al. 2014). We 
used day-time urine and plasma samples, obtained the same day, and matched for age, gender 
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and eGFR.MALD-MS experiments were carried out on freshly collected second morning urine 
samples from 2 men age-matched with divergent genotype. 
Urine collection protocols for uromodulin MALD-MS experiments have been approved by the 
ethical committee of the Université Catholique de Louvain. For the two Swiss population-based 
studies CoLaus and SKIPOGH protocols were approved by local ethical committees. All 
participants provided written informed consent (Pruijm M. et al. 2016). 
Uromodulin measurements: Urine and plasma uromodulin were measured by a validated in-
house ELISA as previously described (Youhanna S. et al. 2014; Olden M. et al. 2014). In brief, 
we used a sheep anti-human uromodulin antibody (K90071C; Meridian Life Science, Memphis, 
TN) as the capture antibody, a mouse monoclonal anti-human Tamm-Horsfall protein antibody 
(CL 1032A; Cedarlane Laboratories, Burlington, NC) as the primary antibody, and a goat anti-
mouse IgG (H+L) horseradish peroxidase–conjugated protein (172.1011; Bio-Rad Laboratories, 
Inc., Hercules, CA) as a secondary antibody. Standard curve was established using human 
uromodulin (AG 733, stock solution: 100 µg/ml; EMD Millipore, Temecula, CA). This assay has 
a sensitivity of 2.8 ng/ml and a linearity of 1.0. The inter-assay and intra-assay variability are 
3.28 % and 5.46 %, respectively and the detection range is between 3.9 and 500 ng/ml. We 
diluted urine samples 1:101 in double distilled water whereas plasma samples were used without 
any dilution. A commercially available ELISA kit (Euroimmun AG, Lübeck, Germany) was also 
used to measure plasma uromodulin levels following the manufacturer’s instruction. 
Biochemical treatments: De-N-glycosylation was performed on human urine using a set of 
enzymes according to manufacturer’s instructions. The following enzymes were used: Peptide-
N-Glycosidase F (PNGaseF) (New England Biolabs, P0704L) for removal of high mannose, 
hybrid, and complex N-glycans, Neuraminidase (sialidase) (New England Biolabs, P0720S) to 
catalyze the hydrolysis of N-acetyl-neuraminic acid residues and Endoglycosidase H (New 
England Biolabs, P0702S) to cleave within the chitobiose core of high mannose and some hybrid 
type N-glycans from glycoproteins. 
 
Immunoblotting: Sodium dodecyl sulphate-PolyAcrylamide Gel Electrophoresis (SDS-
PAGE) was performed under reducing conditions on human urine samples. Samples were loaded 
after being mixed with Laemmli sample buffer (Bio Rad, USA) and heated for 5 min at 95 °C. 
Proteins were separated on 10 % SDS-PAGE and transferred to polyvinyl difluoride (PVDF, Bio 
Rad Laboratories, USA) membrane (activated with 90 % methanol for 2 min) for Western 
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blotting. Membranes were blocked with 5 % milk for 30 min at room temperature then incubated 
overnight at 4 °C with either sheep anti-human uromodulin antibody (Meridian Life Science, 
Memphis, TN, USA; K90071C) or mouse monoclonal anti-human uromodulin antibody 
(Cedarlane Laboratories, Burlington, NC, USA; CL 1032A) (1:500 in 0.5 % BSA blocking 
buffer). Secondary antibodies were applied for 1 hour at room temperature. We used goat anti-
mouse horseradish peroxidase (HRP) conjugated (1:10,000) (P0447 Dako, Denmark), or 
polyclonal rabbit anti-sheep HRP conjugated (1:1000) (P0163, Dako, Denmak). Antigen-
antibody reaction was detected by using enhanced chemiluminescence (Immun-Star HRP, Bio-
Rad) and light-sensitive film (GE Healthcare, Glattbrugg, Switzerland). The molecular weight 
was estimated by running the Precision Plus Protein™ All Blue standard (Bio-Rad). 
Two-dimensional gel electrophoresis: Urine samples were diluted in 8 M urea, 2 M thiourea, 4 % 
CHAPS, 0.05 % Zwittergent, 3 mM TCEP, 100 mM DeStreak and 0.5 % IPG buffer pH 3-5.6. 
The samples were loaded on Immobiline Dry strip pH 3-5.6, 7 cm for the first dimension (total 
focusing run was 50,000 Vh). IPG strips were sequentially reduced and alkylated prior to the 2nd 
dimension electrophoresis with SDS-PAGE 7.5 %. Proteins were electroblotted to nitrocellulose 
membrane for 2 h at 390 mA. Membranes were blocked overnight in TBS-T buffer containing 5 
% milk. 
Uromodulin N-glycans isolation and analysis: To retrieve and study uromodulin N-
glycans we adapted the following procedure: first we precipitated uromodulin from urine 
following the protocol of Tamm and Horsfall (Tamm I. et al 1950), and then we isolated 
uromodulin on coomassie-stained 10 % SDS-PAGE. Uromodulin bands were incubated with 
PNGase F enzyme (100 U/ml in 20 mM ammonium bicarbonate) overnight at 37 °C as described 
by Küster et al. (Küster B. et al. 1997) the second day supernatant containing N-glycans was 
collected and stored in -20 °C until MALDI-MS analysis.  
Matrix-assisted laser desorption ionization-mass spectrometry (MALDI-MS) 
Uromodulin N-glycans isolated from both genotypes were permethylated using the sodium 
hydroxide procedure, as described previously and MALDI-TOF-MS data were acquired using an 
ABSciex 4800 MALDI-TOF/TOF mass spectrometer (Applied Biosystems) (Hülsmeier AJ. et al. 
2011). 
Data analysis: Quantification of immunoblotting bands was done using ImageJ1 
software. Nycthemeral data curve fitting was performed on Acro 3.5. Statistical Package for 
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Social Sciences (SPSS) version 19 (IBM Corp., Armonk, NY, USA) was used for curves 
distribution, Pearson correlation coefficient, paired t-test and analysis of variance (ANOVA). 
Continuous data reported as mean ± SEM. 
The N-glycans were annotated from the MALDI MS spectra using the Cartoonist 
algorithm (Goldberg D. et al. 2005). Peak lists were exported from the Data Explorer Software 
Version 4.9 (Applied Biosystems) to MS-Excel. The areas of the identified N-glycan signals 
were normalized to the sum of all glycan signals, and the standard deviations for the relative 
peak areas were computed using Graph Pad Prism Version 6.01. Six (GG genotype) and seven 
(TT genotype) technical replicates were analyzed. 
Results 
 
UMOD promoter variant and urinary levels of uromodulin in the general population 
The UMOD promoter variants (rs12917707 and rs4293393) have consistently been associated 
with the risk for CKD and hypertension in the general population. These variants are located in a 
large linkage disequilibrium (LD) block that encompasses exons 3, 4 and 6 where N-
glycosylation sites are encoded (Figure 1). 
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Figure 1: Variants in the UMOD locus and structure of uromodulin.a) UMOD promoter variants 12917707 
and 4293393 are a LD block encompassing other variants from exons 3, 4 and 6. b) Amino acid sequence 
of human uromodulin with N-glycosylation sites in red. Exons are indicated as follow: exon 3 highlighted 
in grey, exon 4 highlighted in dark grey and exon 6 highlighted in grey and underlined. c) The structure of 
uromodulin consists of 3 epidermal growth factor (EGF)-like domains, a central domain named D8C it 
contains eight conserved cysteines, a zona pellucida (ZP) domain, and a glycosylphosphatidylinositol 
(GPI)-anchoring site. N-glycosylation sites are indicated in red. 
 
We analyzed the effect of these variants on uromodulin levels in spot urine samples from the 
CoLaus population (n = 5,126) (Figure 2).  
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Figure 2: Effect of UMOD variant on uromodulin levels. a) Normal distribution of log-transformed urine 
uromodulin levels in a Swiss cohort CoLaus among genotype categories of UMOD variant rs12917707 GG 
n = 3,463, GT n = 1,502, TT n = 197. The red line indicated the mean of uromodulin in the general 
population (31.03 ± 0.38 µg/ml; n = 5,126). b) Average urine uromodulin levels (absolute and normalized 
to creatinine) in genotype categories. GG: 33.23 ± 0.51 µg/ml; 22.73 ± 0.26 mg/g creatinine, GT: 27.23 ± 
0.58 µg/ml; 18.60 ± 033 mg/g creatinine, TT: 21.36 ± 1.17 µg/ml; 13.86 ± 0.63 mg/g creatinine. 
Uromodulin levels (absolute and normalized to creatinine) were significantly different among genotype 
categories (p < 0.001). *** p < 0.001. 
 
The distribution of uromodulin based on the rs12917707 UMOD genotype is normal in all 
categories (Figure 2A). The average values of uromodulin (absolute and normalized to 
creatinine, respectively) are: general population (31.03 ± 0.38 µg/ml; 21.19 ± 0.22 mg/g 
creatinine; N 5,126); GG (risk) carriers (33.23 ± 0.51 µg/ml; 22.73 ± 0.26 mg/g creatinine; N = 
3,463); GT carriers (27.23 ± 0.58 µg/ml; 18.60 ± 033 mg/g creatinine; N = 1’502); and TT 
(protective) carriers (21.36 ± 1.17µg/ml; 13.86 ± 0.63 mg/g creatinine; N = 197) (Figure 2B). 
These data demonstrate the major effect of the rs12917707 variant, with a dose dependent effect 
of the G allele on the levels of uromodulin in urine. As compared to the homozygous TT 
(protective) carriers, the homozygous GG (risk) carriers have a 2-fold increase in the indexed 
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uromodulin levels in urine, whereas the heterozygous GT carries show intermediate levels. 
Changes of uromodulin levels among genotype categories were significant (p < 0.001). 
 
Influence of UMOD promoter variant on plasma uromodulin levels 
We investigated the effect of the UMOD variant rs12917707 on the level of circulating and 
urinary uromodulin in samples from the urban Swiss SKIPOGH cohort matched for age, gender 
and eGFR (Table 1). 
 
  
Low uUMOD 
(N = 23) 
High uUMOD 
(N = 23) P values
 
Age 53.5 ± 3.23 49.4 ± 3.05 0.54 
     
uUMOD (µg/ml) 6.62 ± 0.90 80.35 ± 7.81 < 0.01 
uUMOD (mg/g creat) 10.7 ± 1.59 65.8 ± 10.7 < 0.01 
pUMOD (ng/ml) 23.1 ± 2.36 34.1 ± 3.26 0.013 
     
eGFR (mL/min/1.73 m2) 90.2 ± 3.73 98.0 ± 3.38 0.22 
 
Table 1 A: Plasma and urine levels of uromodulin levels in 23 pairs of samples matched for age, gender 
and eGFR form the general population (SKIPOGH). Gender distribution: 11M/12F. u: urine; p: plasma. 
 
  TT (N = 21) GG (N = 21) P value 
Age 53.4 ± 3.22 54.3 ± 3.27  
uUMOD (µg/ml) 14.2 ± 2.87 31.7 ± 4.33 < 0.01 
uUMOD (mg/g creat) 17.2 ± 2.76 40.5 ± 4.65  < 0.01 
    
pUMOD1 (ng/ml) 10.6 ± 1.73 17.6 ± 1.24 < 0.01 
pUMOD2 (ng/ml)  34.5 ± 3.22 59.4 ± 4.16 < 0.01 
    
eGFR (mL/min/1.73 m2) 91.3 ± 3.60  91.6 ± 3.71 0.95 
 
Table 1 B: Plasma and urine uromodulin levels in GG vs TT (rs12917707) categories in SKIPOGH samples. 
pUMOD1: plasma uromodulin levels measured with In-house assay (Youhanna S. et al. 2014); pUMOD2: 
plasma uromodulin levels measured with commercial assay (Euroimmun AG, Lübeck, Germany). 
 
Gender distribution: 8M/13F Subjects homozygous for the G (risk) allele showed significantly 
higher levels of uromodulin in the urine (both absolute and indexed to creatinine) and in the 
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plasma. These differences were observed when using either our well-characterized ELISA or 
with a commercial kit, and with normal eGFR values. 
The potential link between the urine and plasma levels of uromodulin was further analyzed in a 
subset of subjects from SKIPOGH. A large variation in urine uromodulin, independent of the 
genotype, was observed in this cohort, the 5th and 95th percentile values being 5.58 µg/ml (5.87 
mg/g creatinine) and 58.3 µg/ml (69.46 mg/g creatinine) respectively. We measured plasma 
uromodulin level in two subgroups matched for age and eGFR but with divergent urine 
uromodulin levels (low urine level: 6.67 ± 0.86 µg/ml; 10.6 ± 1.53 mg/g creatinine, n = 23; and 
high urine level: 80.3 ± 7.81 µg/ml (65.8 ± 10.75 mg/g creatinine, n = 23) (Table 1). Individuals 
in the high urine uromodulin category showed significantly higher plasma uromodulin levels 
(34.05 ± 3.26 ng/ml compared to 23.73 ± 2.31ng/ml; P = 0.013). 
 
Effect of UMOD variant on uromodulin immunoreactivity and N-glycosylation 
The rs12917707 variant is located in an LD block comprising exons 3, 4 and 6 that code for Asn 
residues involved in N-glycosylation sites, suggesting that this variant may affect either the 
glycosylation site usage or the maturation of N-glycans along the secretory pathway. 
We investigated the potential effect of the rs12917707 UMOD variant on the biochemical 
properties of uromodulin in urine samples from CoLaus (10 pairs of human urine samples GG vs 
TT) matched for age, gender and eGFR, using 3 different anti-uromodulin antibodies. 
Immunoblotting experiments were done by loading the same amount of uromodulin (based on 
ELISA measurements) for all samples (Figure 3). 
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Figure 3: Uromodulin immunoreactivity among UMOD genotypes (rs12917707). Representative western 
blot analysis (10 % SDS-PAGE) of human urine samples (10 pairs) (5ng/well) showing uromodulin 
immunoreactivity among genotype categories of UMOD rs12917707 with different anti-uromodulin 
antibodies (Meridien and Abcam are polyclonal sheep anti-uromodulin (1:500) and Cederlane is 
monoclonal mouse anti-uromodulin (1:500)): a) Mature (N-glycosylated) uromodulin immunoreactivity. 
Significant difference observed between genotypes in antibodies categories. b) Peptide-N-Glycosidase F 
deglycosylated uromodulin immunoreactivity among UMOD genotypes (rs12917707). Significant 
difference observed between genotypes in antibodies categories expect for Cedarlane mouse antibody. * p 
< 0.05. 
 
Samples harbouring GG genotype of rs12917707 consistently showed higher signal intensity 
than the TT samples with the 3 antibodies when quantifying glycosylated uromodulin bands 
(Figure 3A). Of interest, these systematic differences in immunoreactivity were no longer 
observed after treatment with PNGase F to remove the totality of N-glycans. Assessment of 
bands intensity of deglycosylated protein shows uniform signal using the mouse monoclonal 
antibody while the difference among genotype remains unchanged with the two polyclonal 
antibodies (Figure 3B). These data suggest that difference of immunoreactivity can be explained 
at least in part by a difference in the N-glycans reflecting the two different UMOD genotypes.  
To gain insight into the glycan modifications responsible for the different immunoreactivity, 
selected urine samples were subjected to two additional treatments affecting the N-glycan 
composition. Sialidase was used to remove sialic acid and Endo H to remove glycans that have 
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not been modified in the Golgi (high mannose) reported only on 1 site on mature uromodulin. 
We observed a difference in immunoreactivity between genotypes (GG vs TT) as well as within 
the same genotype category. 
The observed modification in immunoreactivity among genotypes has been additionally 
investigated using two-dimensional gel electrophoresis (2-DGE) on two pairs of human urine 
samples selected from the above-mentioned samples. Analysis showed different isoelectric point 
(IP) among genotypes in the fully glycosylated state (Figure 4). 
 
 
Figure 4: A representative two-dimensional gel (2D gel) analysis for uromodulin among UMOD genotypes 
(rs12917707). Comparison of the isoelectric point of mature uromodulin (fully glycosylated) versus de-N-
glycosylated and desialylated uromodulin was performed in 2 pairs of human urine samples. Human urine 
samples were treated with PNGase F or sialydase (following manufacturer’s protocol) and loaded on a 2D 
gel. 
 
Samples with the GG genotype displayed lower IP than those with the TT genotype. This 
difference was abolished after removal of N-glycosylation with PNGase F or desialylation with 
sialidase, indicating that increased sialylation on N-glycans contributes to the acidic IP of 
uromodulin of the GG genotype. 
 
MALDI-MS analysis of uromodulin glycans 
N-glycans were released from uromodulin by in-gel digestion with PNGase F and analyzed by 
Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS). The N-glycan 
profiles of the GG- and TT-genotypes were compared and the identified glycans were in 
agreement with glycosylation profiles described previously (Halim A. et al. 2012; Hong CY. et 
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al. 2013). A tendency of increased relative amounts of tetra-antennary, tetra-sialylated N-glycans 
in the GG-genotype related uromodulin was apparent (Figure 5A). 
 
 
Figure 5A: Uromodulin N-glycans profile among UMOD genotypes (rs12917707). A comparison profile 
of uromodulin N-glycans of GG vs TT samples. The average relative peak areas for each glycan are plotted 
(error bars indicate SEM). Glycans detectable at least 3 times were normalized to the sum of peak areas 
within a MALD-MS acquisition. 
 
Nevertheless, a statistically significant difference between the genotypes could not be calculated, 
due to variability in glycan compositions between samples analyzed. We observed an overall 
difference in the uromodulin N-glycan compositions between the genotypes, with some glycans 
being exclusively present in the TT- or GG-genotype (Figure 5B). 
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Figure 5B: Uromodulin N-glycans profile among UMOD genotypes (rs12917707). A representative 
MALDI-MS profile of permethylated N-glycans from urinary uromodulin GG and TT subjects (1 pair). 
Glycans highlighted in dark blue are only detected in either TT sample or in GG sample. 
 
Discussion 
 
In this study, we show for the first time that a common variant in the promoter of UMOD 
(rs1297707), consistently associated with the risk of CKD and hypertension in the general 
population, mediates the urinary excretion of uromodulin and also affects the levels of 
circulating uromodulin. The latter is approximately 1000-fold lower than the urine levels, which 
were shown to follow a nycthemeral cycle. The UMOD variant, located in a large LD block 
covering 6 exons of the gene, is associated with changes in the immunoreactivity of uromodulin, 
secondary to modified N-glycosylation composition. These biochemical changes were not 
caused by modifications in the coding sequence of UMOD. 
The common variant of UMOD promoter rs12917707 is in total LD with other UMOD promoter 
variants of which major alleles have been identified as risk alleles for several renal diseases such 
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as chronic kidney disease (CKD), kidney stones and hypertension in different genome wide 
association studies (GWAS) (Köttgen A. et al. 2009; Köttgen A. et al. 2012; Padmanabhan S. et 
al. 2010; Reznichenko A. et al. 2012). As risk alleles have been linked to elevated urinary 
uromodulin levels in the general population (Olden M. et al. 2014), higher uromodulin levels 
were consequently linked to higher predisposition to previously mentioned renal disorders. In 
this study we confirm that the distribution of urinary uromodulin levels, whether normalized to 
creatinine or not, is genotype-dependent: risk allele G accounts for higher uromodulin levels than 
minor allele T. 
Our efforts to investigate modulators of plasma uromodulin levels in an age-matched 
group with normal renal function proved that UMOD variant rs12917707 affects significantly 
variations in plasma uromodulin. Higher plasma uromodulin levels are observed within subjects 
displaying the major allele G and high urinary uromodulin. Very few inconsistent studies have 
investigated serum uromodulin levels as a marker for renal function (Risch L. et al. 2014) or for 
disease progression (Prajczr S. et al. 2010) but so far any study had interrogated plasma 
uromodulin changes with regards to an important modifier of urinary uromodulin UMOD 
variant. 
We think that elevated urinary and plasma uromodulin observed in the presence of risk 
allele may result from early damage in the tubular interstitium thus preceding TAL damage. 
These novel findings correlating urinary uromodulin levels to plasma uromodulin together with 
genotype influence of UMOD promoter variant on both uromodulin levels may give an insight 
on the role of this variant. 
The SNPs within the promoter region of uromodulin gene are an LD block encompassing 
exons 3, 4 and 6. These exons encode for N-glycosylation sites which are essential for functions 
attributed to uromodulin, mainly the defense against urinary tract infections through binding to 
type I fimbriated Escherichia coli via its high-mannose residues (Bates JM. et al. 2004). In an 
attempt to elucidate the potential mechanisms of the relationship between UMOD promoter 
variants and renal dysfunction we scrutinized uromodulin glycosylation patterns among SNP 
genotypes using samples with divergent genotype and employing several technics. We observed 
genotype-dependent variations in signal detection and IP; samples exhibiting the minor allele T 
display lower immunoreactivity and higher IP compared to samples with the major allele G. 
These discrepancies between genotypes were abolished after de-N-glycosylation indicating that 
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differences in glycan composition may explain the perceived divergence. Additionally, N-glycan 
profiling by MS-MALDI in a pair of human urine samples matched for age and gender but 
genotype divergent indicates that indeed N-glycan composition differs among genotypes. Of 
note, this difference is not an outcome of variation in food composition rather an outcome of 
cellular synthesis. Recognizing the importance of N-glycans in the protective role of uromodulin 
against urinary tract infection, toxic metabolite in the urine (Parsons CL. et al. 2011) and kidney 
stone formation (Viswanathan P. et al. 2011) thus alteration of glycan on uromodulin surface 
may have considerable consequences on protein functionality. Considering these data, together 
with the effect of UMOD variant on urinary uromodulin levels, we hypothesize that modification 
of glycan composition could be a process by which cellular machinery adapts to the increased 
production of this glycoprotein in the case of risk allele. Further investigations are needed to 
better explore the effect of UMOD variant on uromodulin N-glycosylation and its consequences 
on its function particularly that the risk allele is present in high frequency in the general 
population. 
We acknowledge that this study has limitations. We have investigated glycans 
composition among genotypes by MALDI-MS only in one pair of subject. This is due to the 
difficulty in finding subjects homozygous for minor allele of UMOD promoter variant since it 
has a genotype frequency of 4 % in the general population. 
The advantages of this work are: homogeneous sample size, correlations plasma and urine, 
morning samples, optimalized for uromodulin ELISA, genotype known, matching for age, 
gender and eGFR, large cohorts allowing comparison of the rare homozygous state for protective 
variants. 
In conclusion, our study provides novel evidence that UMOD promoter variant rs12917707 
influences the excretion of plasma uromodulin and the biochemical property of urine 
uromodulin, thus giving insights into mechanisms how this variant leads to renal disorders. 
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V. Uromodulin excretion: Association with clinical and genetic 
factors in the general population 
 
This chapter is a summary of the following published articles: 
 
1-Associations of Urinary Uromodulin with Clinical Characteristics and Markers of Tubular 
Function in the General Population. 
Pruijm M., Ponte B., Ackermann D., Paccaud F., Guessous I., Ehret G., Pechère-Bertschi A., 
Vogt B., Mohaupt MG., Martin PY., Youhanna SC., Nägele N., Vollenweider P., Waeber G., 
Burnier M., Devuyst O., Bochud M. Clin J Am Soc Nephrol. 2016; 7; 11 (1): 70-80. 
 
2-Clinical, Genetic, and Urinary Factors Associated with Uromodulin Excretion. 
Troyanov S., Delmas-Frenette C., Bollée G., Youhanna S., Bruat V., Awadalla P., Devuyst O., 
Madore F. Clin J Am Soc Nephrol. 2016; 7; 11 (1): 62-9.  
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Introduction 
 
Uromodulin is the most abundant protein in the urine under normal physiological conditions and 
it is secreted exclusively by the epithelial cells of the thick ascending limb (TAL). Several 
biological roles have been attributed to this protein, recent studies showed an association 
between uromodulin secretion and the regulation of sodium transport in the thick ascending limb 
(TAL) (Trudu M. et al. 2013; Mutig K. et al. 2011), other preliminary studies have suggested an 
association between uromodulin and estimated glomerular filtration (eGFR) but these findings 
still lack the confirmation within cohorts of large sample size (Thornely C. et al. 1985; Reinhart 
HH. et al. 1991). 
Mutations in the UMOD gene have been shown to cause uromodulin-associated kidney 
diseases (UAKD). UAKD are autosomal dominant disorders characterized by hyperuricemia and 
gout early in life, alteration of urinary concentrating ability, and tubulointerstitial fibrosis with 
occasional cysts at the corticomedullary junction. UAKD invariably lead to chronic renal failure 
during the third to seventh decade of life. The identified mutations (mostly missense, affecting 
cysteine residues) affect the biosynthesis of uromodulin and lead to its accumulation in the 
endoplasmic reticulum (ER) thus decreased uromodulin excretion. These events may cause ER 
stress and tubulointerstitial injury leading eventually to progressive renal damage (Rampoldi L. 
et al. 2011). In addition to its direct involvement in UAKD, recent genome wide association 
studies (GWAS) pointed at uromodulin as a risk factor for CKD, kidney stones, and hypertension 
(Köttgen A. et al. 2012). Nevertheless, the identification of common and rare variants of UMOD, 
associated with common traits and monogenic diseases of the kidney, points toward the high 
relevance of uromodulin biology. 
In this work, we use clinical, biological and genetic information from several large 
cohorts to better understand the function and the clinical significance of uromodulin including 
factors influencing the glycoprotein excretion and its relationship with eGFR. 
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Material and Methods 
 
Studied populations and functional parameters 
Our work analyses and study investigations were conducted in 3 populations. Two Swiss 
population-based studies: the Swiss Kidney Project on Genes and Hypertension (SKIPOGH) 
(2009-2012). n = 817; the Cohort Lausannoise (CoLaus) (2003-2006) n = 5,706 and a subset of 
individuals chosen from a Canadian cross-sectional study CARTaGENE (CaG) (2009-2015) n = 
46. Individuals in the SKIPOGH study were randomly selected from the general population in 
Bern, Lausanne and Geneva. Participants were adult and European descent. Clinical and 
demographic data were collected from all participants in addition to complete physical 
examination, blood sampling after overnight fasting, 24 h urine collection and renal 
ultrasonography (Ponte B. et al. 2014). Participants in the CoLaus study were adults from 
Lausanne having a European descent. Anthropometric data were collected from participants in 
addition to morning spot urine and blood sampling after overnight fasting (Firmann M. et al. 
2008). The CARTaGENE study included participants from Quebec 40-69 years old. At the study 
visit medical history (including medication usage information) was gathered from all participants 
in addition to physical examination, blood and morning spot urine collection (Awadalla P. et al. 
2013). All study protocols were approved by local ethical committees. The baseline 
characteristics for the study participants are shown in Table 1. 
We analyzed clinical and biological correlates of uromodulin excretion as well as its 
association with markers of glomerular and tubular function in SKIPOGH and CoLaus. We also 
established and confirmed associations of uromodulin levels with relevant parameters in serum 
and urine in addition to patients’ medical history within CARTaGENE individuals. 
Renal ultrasound was performed on SKIPOGH participants according to a standardized 
procedure described by Pruijm M. et al. (Pruijm M. et al. 2013) Renal volume was calculated as 
0.523 x length x width x transverse diameter (Jones TB. et al. 1983). All ultrasounds were 
performed by one experienced operator at each center. 
Laboratory measurements were carried out using standard clinical laboratory methods. 
Serum measurements included: urea, creatinine, electrolytes, uric acid, and glucose. Urinary 
measurements included: glucose, electrolytes, uric acid, creatinine, osmolality and albumin. The 
CKD-EPI formula was used to calculate eGFR (Levey AS. et al. 2009). 
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In SKIPOGH, a 24 h urine collection was started on the day of the study visit and 
returned the next day by the participant. Incomplete urine collection was defined as a volume 
less than 300 ml per 24 h, a 24 h urinary creatinine excretion of less than 0.1 mmol/kg body 
weight, or if reported as incomplete by the participant. Urine collections containing > 0.4 
mmol/kg creatinine were also excluded from further analysis (Bankir L. et al. 2008). 
In CoLaus and CARTaGENE, urinary uromodulin, creatinine, electrolytes concentrations 
and osmolality were measured in morning spot urine samples. 
Urinary biochemical parameters were measured from samples stored at -80 °C, using the same 
biochemical platform at the University of Zurich. The 24 h urinary osmolar excretion in mosm 
was calculated as: 24 h osmolality x 24 h urinary volume. 
Uromodulin was measured from urinary samples stored at -80 °C at the University of 
Zurich (Youhanna S. et al. 2014). Urinary creatinine levels were measured using Beckman 
Coulter Synchron System Creatinine Assay (Unicell DxC Synchron Clinical System) following 
the manufacturer’s instructions. 
Individuals from the CARTaGENE population with genotype data were selected from an 
ongoing sub-study on common variant associations in cardiovascular disease: top 150 and 
bottom 150 Framingham scores for both men and women (n = 600) and top and bottom 100 
patients on the basis of the vascular rigidity index for both men and women (n = 400). 
Genotyping was performed using the Illumina HumanOmni2.5™ BeadChip. Candidate SNPs 
were chosen based on the meta-analysis done by Olden et al. (Olden M. et al. 2014) where 
rs12917707 located near UMOD on chromosome 16 had the strongest association with urinary 
uromodulin levels. The rs4293393 variant located in the promoter region is in perfect linkage 
disequilibrium with rs12917707 in the HapMap CEU and shows a frequency within the 
CARTaGENE identical to HapMap CEU (International HapMap consortium 2005). The SNP 
rs12446492 in the adjacent gene PDILT (protein disulfide isomerase-like, testis-expressed) also 
independently influenced uromodulin levels (Olden M. et al. 2014). These 2 variants, partly in 
linkage disequilibrium (D’ = 0.674) in the Canadian cohort, were included as genetic predictors 
of uromodulin excretion. 
All studied parameters not normally distributed were log transformed. Pearson’s or Spearman's 
correlation tests were used to check for correlations, t-test or Mann-Whitney U tests were used to 
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check for variance, multivariate linear regression was used to study associations between 
uromodulin and urinary parameters. 
Results 
 
Cohort n Women % 
Age 
 yr 
BMI 
kg/m2 
eGFR 
ml/min per 
1.73 m2 
Urine uromodulin 
µg/ml 
Urine 
uromodulin 
mg/g creatinine 
Colaus 5706 53 53 ± 11 25.7 ± 5 86 ± 15 25.7 (14.5 - 39.9) 18.2 (10.8 - 27.8) 
SKIPOGH 817 53 45 ± 17 24.5 ± 4 98 ± 17 26.9 (17.4 - 34.9) 30.5 (19.2 - 44.0) 
CARTaGENE 946 51 54 ± 9 26.7 ± 3 90 ± 14 35.2 (11.3 - 42.1) 14.2 (7.3 - 28 .2) 
 
Table 1: Baseline characteristics of the participants in the studied cohorts. Values are expressed as mean ± 
SEM, median (25th - 75th percentiles) or as percentage. 
 
Uromodulin and gender 
 
 
Figure 1: Distribution of uromodulin excretion (24 h urine) and concentration (spot urine) according to 
gender. 
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There were no gender dissimilarities in uromodulin concentration (in CoLaus, spot urine) nor in 
24 h uromodulin excretion (SKPOGH). Differences observed in uromodulin to creatinine ratio 
are due to lower creatinine values in women (Figure 1). Since creatinine levels are body mass- 
and age-dependent adjusting for creatinine can cause an overcorrection. 
Uromodulin and markers of glomerular filtration 
Association between uromodulin excretion and eGFR were significantly positive in the assessed 
cohorts. In the Canadian cohort uromodulin excretion paralleled the eGFR (Figure 2 A). This has 
also been confirmed in both Swiss cohorts whether with creatinine-based or cystatin-based eGFR 
except that this association was positive only when eGFR was < 90 ml/min per 1.73 m2 (Figure 
2B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: A) Association of eGFR with uromodulin excretion in CARTaGENE (P < 0.001) (error bars 
indicate SD). B) Scatterplot showing the association of eGFR with urinary uromodulin excretion in 
SKIPOGH. 
 
Uromodulin and anatomic markers of renal mass 
In SKIPOGH, renal grey-scale B-mode ultrasonography was performed. Study participants had 
their 24 h uromodulin excretion rate positively and linearly associated with renal length and 
volume in univariate and multivariate models (Figure 3). 
A B 
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Figure 3: Age- and gender-adjusted associations of square rooted 24 h uromodulin excretion with kidney 
volume (A) and kidney length (B). 
 
Genetic determinants of uromodulin excretion 
Variants in the UMOD promoter region, such as rs4293393, are well documented to influence 
the excretion of urine uromodulin (Trudu M. et al. 2013). We confirm these findings in the 
Canadian cohort. Additionally, we find that SNP rs12446492 in the PDILT gene adjacent to the 
UMOD gene is predictive of uromodulin excretion. TT genotypes from both SNPs show highest 
levels of uromodulin (Figure 4). 
 
 
Figure 4: Associations of rs4293393 and rs12446492 genotypes with uromodulin excretion (Error bars 
indicate SD). 
 
A B 
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Urinary parameters and uromodulin excretion 
We assessed the association of uromodulin levels with urine electrolytes, uric acid and 
glycosuria. In the Canadian cohort this association was inversely correlated with the presence of 
glycosuria. Glycosuria levels we considered positive if > 0.5 mg/g creat. (Santer R. et al. 2010). 
 
 
 
 
 
 
 
 
 
Figure 5: Variations of uromodulin levels among glycosuria categories. Uromodulin levels consistently 
decreased in the presence on glycosuria (error bars indicate SEM). 
 
Univariate analysis showed strongly significant associations between uromodulin and 
electrolytes (Na2+, K+, Cl-, Mg2+, Ca2+), fractional excretions of uric acid (FE-UA) sodium (FE-
Na) and urine osmolality. Our results were consistent in the studied cohorts. These associations 
persisted when multivariate analysis was applied correcting for age, gender, BMI and eGFR. 
Some associations were weakened or lost when correction for creatinine was included (Table 2). 
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Variable  
Unadjusted   Model 1   Model 2 
Coefficient (95 % CI) P Value Coefficient (95 % CI) P Value Coefficient (95 % CI) P Value 
SKPOIGH (24 h 
urine excretion)            
Urinary sodium  2.07 (1.60 to 2.54)  <0.001  1.26 (0.81 to 1.72)  <0.001  0.98 (0.53 to 1.43)  <0.001 
Urinary chloride  2.16 (1.52 to 2.79)  <0.001  1.22 (0.61 to 1.83)  <0.001  0.90 (0.29 to 1.50)  0.004 
Urinary potassium  1.10 (0.74 to 1.47)  <0.001  0.43 (0.11 to 0.75)  0.01  0.07 (-0.23 to 0.37)  0.64 
Urinary magnesium  0.24 (0.17 to 0.32)  <0.001  0.12 (0.05 to 0.20)  0.001  0.06 (-0.01 to 0.13)  0.09 
Urinary calcium  0.38 (0.24 to 0.52)  <0.001  0.23 (0.09 to 0.4)  0.002  0.16 (0.02 to 0.30)  0.03 
Urinary osmolality 0.82 (0.63 to 1.01)  <0.001  0.54 (0.37 to 0.70)  <0.001  0.33 (0.18 to 0.48)  <0.001 
CoLaus (Spot urine)            
Urinary sodium 1.87 (1.40 to 2.34)  <0.001  1.59 (1.14 to 2.04)  <0.001  1.63 (1.14 to 2.11)  <0.001 
Urinary chloride 3.88 (3.34 to 4.42)  <0.001  3.45 (2.93 to 3.98)  <0.001  2.38 (1.82 to 2.94)  <0.001 
Urinary potassium 6.40 (5.90 to 6.91)  <0.001  6.14 (5.64 to 6.65)  <0.001  2.63 (2.15 to 3.12)  <0.001 
Urinary magnesium 0.81 (0.71 to 0.9)  <0.001  0.77 (0.67 to 0.86)  <0.001  0.02 (-0.07 to 0.10)  0.72 
Urinary calcium 0.59 (0.45 to 0.73)  <0.001  0.54 (0.40 to 0.68)  <0.001  0.09 (-0.06 to 0.23)  0.25 
Urinary osmolality 0.74 (0.69 to 0.79)   <0.001   0.68 (0.63 to 0.73)   <0.001   0.24 (0.20 to 0.29)   <0.001 
 
Table 2: Association of urinary osmolality and electrolytes with urinary uromodulin in Swiss cohorts. 
Model 1: adjusted for age, sex, body weight, eGFR and 24 h urine volume (SKIPOGH only). Model 2: 
adjusted as for model 1 plus urinary creatinine concentration in CoLaus and 24 h creatinine excretion in 
SKIPOGH. 95 % CI: 95 % confidence interval. 
 
To check for independent factors associated with uromodulin excretion we carried out in the 
CARTaGENE population a stepwise multivariate linear regression including variables that 
showed significance in univariate analysis. Higher uromodulin levels were independently 
associated with eGFR, TT genotypes from rs4293393 and rs12446492, FE-Na and FE-UA. On 
the other hand, glycosuria was associated with lower levels of uromodulin excretion. FE-UA 
explained most of the variability in the model (Table 3). 
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Variables Standardized-ß P Value 
GFR CKD-EPI (ml/min per 1.73 m2) 0.11 0.001 
rs4293393 (TT vs CC vs CT) 0.07 0.04 
rs12446492 (TT vs AA vs AT) 0.09 < 0.01 
FE-Na 0.1 < 0.01 
Presence of glycosuria -0.07 0.02 
FE-UA 0.29 < 0.01 
 
Table 3: Multivariate predictors of uromodulin in CARTaGENE. 
 
Discussion 
 
In this study, we evaluate determinants of uromodulin excretion in three large cross-sectional 
studies. We show a correlation between uromodulin excretion and several clinical, genetic and 
urinary variables. Urine uromodulin excretion is positively associated with renal mass, renal 
volume, eGFR, urine electrolytes and osmolality suggesting that urinary uromodulin can be 
considered as a marker for tubular functions and mass. Conversely, we show that uromodulin 
excretion decreases with age and in the presence of glycosuria. We also confirm that urinary 
uromodulin levels are influenced by genetic variants located in the UMOD promoter and the 
PDILT gene. 
The association of uromodulin with renal volume and renal mass suggests that 
uromodulin can be considered as a marker for tubular mass reflecting tubular number. Also, the 
validation of a positive relationship between uromodulin and eGFR on one hand and the decline 
of uromodulin excretion with age on the other hand, imply that uromodulin reveals tubular 
activity and that the amount of functional tubules can be associated with uromodulin excretion 
levels. 
A decrease in uromodulin excretion is documented in the presence of diabetes mellitus 
indicators such as glycosuria while eGFR levels remain normal. Diabetes might be inducing a 
toxic effect on renal tubular cells leading to an underlying early tubular dysfunction independent 
of eGFR. These findings are coherent with a study performed on CKD patients with diabetes but 
without glomerular dysfunction (Möllsten A. et al. 2010). Confirmation of these results is needed 
in a large diabetic-specific study. Moreover, it has been shown that glycosuria can affect the 
TAL activity thus modulating uromodulin excretion (Riazi S. et al. 2006). 
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In the studied cohorts, changes in uromodulin levels correlate positively with changes in 
urinary electrolytes and urine osmolality. Uromodulin excretion (spot urine and 24h urine) 
parallels sodium, potassium, chloride, calcium and magnesium urinary excretion, indicating that 
uromodulin production modifies tubular handling of these electrolytes and reflects tubular 
function. Despite the robustness of these associations, the dietary effect on sodium, chloride and 
potassium excretion and tubular handling should not be ignored unlike calcium excretion, which 
is less affected by the dietary intake hence reflecting the TAL function more closely. Urine 
osmolality reveals tubular activity, therefore its positive association with uromodulin supports 
the above-mentioned conclusion of uromodulin being a good indicator of tubular activity. These 
findings are in line with results from in vitro and in vivo studies showing uromodulin, as the 
regulator of transport processes in the TAL through increasing the activity of ROMK and 
enhancing the phosphorylation of NKCC2, affects urine concentrating ability (Renigunta A. et 
al. 2011; Mutig K. et al. 2011). The highly significant positive correlation between fractional 
excretion of uric acid and uromodulin could be explained by volume expansion in the proximal 
tubule: an increase in uromodulin excretion would enhance NKCC2 phosphorylation in the TAL 
(Mutig K. et al. 2011) which is hypothesized to cause volume expansion in the proximal tubule 
resulting in declined reabsorption of sodium and uric acid thus a rise in uric acid fractional 
excretion (Scolari F. et al. 2004). These results show that despite the exclusive expression of 
uromodulin in the TAL, a dysfunction in this tubule might affect the function of the adjacent 
proximal tubule. 
This work identifies factors influencing and modulating the excretion of uromodulin in 
the general population. Moreover, it suggests uromodulin as a biomarker for renal tubular 
function in the general population as well as a marker for tubular damage independent of eGFR.  
The strength of this work is the large sample size with detailed information about 
participants; the centralized measurements of uromodulin and urinary parameters using a well-
established method, measurement of renal length and renal mass using a standardized protocol  
whereas the limitations are the lack of ethnic diversity and the limitation in assessing causal 
conclusions because these are cross-sectional studies. 
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Abstract  
 
The importance of vasopressin and/or urine concentration in various kidney, cardiovascular and 
metabolic diseases has been emphasized recently. Due to technical constraints, urine osmolality 
(Uosm), a direct reflect of urinary concentrating activity, is rarely measured in epidemiologic 
studies.We analyzed two possible surrogates of Uosm in 4 large population-based cohorts (total n 
= 4,247) and in patients with chronic kidney disease (CKD, n = 146). An estimated Uosm (eUosm) 
based on the concentrations of sodium, potassium and urea, and a urine concentrating index 
(UCI) based on the ratio of creatinine concentrations in urine and plasma were compared to the 
measured Uosm (mUosm). 
eUosm is an excellent surrogate of mUosm, with a highly significant linear relationship and values 
within 5 % of mUosm (r = 0.99 or 0.98 in each population cohort). Bland-Altman plots show a 
good agreement between eUosm and mUosm with mean differences between the two variables 
within ± 24 mmol/L. This was verified in men and women, in day and night samples, and in 
CKD patients. The relationship of UCI with mUosm is also significant but is not linear and 
exhibits more dispersed values. Moreover, the latter index is no longer representative of mUosm 
in patients with CKD as it declines much more quickly with declining GFR than mUosm. 
The eUosm is a valid marker of urine concentration in population-based and CKD cohorts. The 
UCI can provide an estimate of urine concentration when no other measurement is available but 
should be used only in subjects with normal renal function. 
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Introduction 
 
 The interest in the influence of the antidiuretic hormone vasopressin (ADH or AVP) as a 
significant player in various kidney, cardiovascular and metabolic diseases has been revived 
recently (Torres VE. 2009; Bolignano D. et al. 2010; Cirillo M. et al. 2010; Devuyst O. et al. 
2013). The availability of non-peptide, orally active selective vasopressin receptor antagonists 
(vaptans) (Greenberg A. et al. 2006; Decaux G. et al. 2008) and of a reliable ELISA for the 
measurement of copeptin, a validated surrogate of vasopressin (Morgenthaler NG. 2010; Roussel 
R. et al. 2014), has opened the door for a number of studies addressing the vasopressin/thirst 
pathway and osmoregulation in general (Bankir L. 2013). 
 Independent of the well-known contribution of ADH to various forms of water disorders, 
recent epidemiological studies have shown significant associations between indices of the 
vasopressin/hydration system and the incidence or progression of diseases including chronic 
kidney disease (CKD), autosomal dominant polycystic kidney disease (ADPKD), diabetic 
nephropathy, obesity, metabolic syndrome, and insulin resistance (Bardoux P. et al. 2003; Meijer 
E. et al. 2010; Enhorning S. et al. 2011; Roussel R. et al. 2011; Ho TA. et al. 2013; Devuyst O. et 
al. 2013; Schoen T. et al. 2013; Velho G. et al. 2013; Ong AC. et al. 2015; Ponte B. et al. 2015; 
Roussel R. et al. 2015; Pruijm M. et al. 2016; Roussel R. et al. 2016). A number of experimental 
studies have demonstrated the adverse effects of vasopressin or a low level of hydration in 
animal models of these disorders (Bouby N. et al. 1990; Bardoux P. et al. 2003; Ahrabi AK. et al. 
2007; Perico N. et al. 2009; Koshimizu TA. et al. 2012; Taveau C. et al. 2015). A recent double-
blind, placebo-controlled clinical trial, using a selective vasopressin V2 receptor antagonist, 
tolvaptan, proved to bring significant benefit over a 3 year period in patients with ADPKD and 
well preserved renal function (Torres VE. et al. 2012). 
 Because AVP is difficult to measure due to its small mass, very low circulating 
concentrations, poor stability in vitro, and time-consuming assay, most of the recent studies 
dealing with this hormone rely on the measurement of copeptin (a peptide that is part of the pre-
pro-hormone containing vasopressin) in plasma or, more indirectly, on fluid intake or daily urine 
volume (Clark WF. et al. 2011; Strippoli GF. et al. 2011). Urine osmolarity (Uosm), the most 
direct parameter reflecting the action of AVP on distal tubular segments of the kidney, is rarely 
measured due to technical constraints and is thus usually not available in epidemiologic studies.  
96  
 
Various surrogates of Uosm have been used in clinical studies. They include the specific urine 
density or the refraction index that give only an approximate value of the solute content in the 
urine and are subject to several biases including distortion in the case of proteinuria and poor 
precision of readings. Two other surrogates are the Urine Concentrating Index (UCI) based on 
the handling of creatinine by the kidney (Bankir L. et al. 2007; Perucca J. et al. 2007), and the 
estimated urine osmolarity (eUosm) based on the concentration of the three main osmoles present 
in the urine: sodium, potassium and urea (Perucca J. et al. 2007; Zittema D. et al. 2014). To our 
knowledge, the validity of these two surrogates has not been evaluated in large, population-based 
cohorts with normal or altered renal function. The aim of the present study was to assess the 
value of eUosm and UCI compared to measured Uosm (mUosm) in large population-based and CKD 
cohorts, and to test the influence of sample type, gender and age on these markers. 
Material and Methods 
 
Cohorts 
The general characteristics of the subjects belonging to the different cohorts are presented in 
Table 1. 
 
Table 1: Demographic information about the different cohorts. Means + SEM or median (interval). 
 
Cohort CROATIA-Korcula 
GS:SFHS 
Aberdeen 
GS:SFHS 
Glasgow 
SKIPOGH 
Day 
SKIPOGH  
Night CKD Necker 
N 463 554 2305 925 idem 146 
Sample type  Spot Spot Spot Day period Night period 24 h 
Age, y 58 (19 - 87) 57 (19 - 88) 53 (18 - 93) 47 (18 - 90) idem 64 (17 - 86) 
Gender : M / W %  41 / 59 43 / 57 41 / 59 47 / 53 idem 59 / 41 
BMI 27.97 ± 0.21 27.22 ± 0.22 26.97 ± 0.21 25.03 ± 0.15 idem 24.16 ± 0.30 
mUosm, mosm/kg 
H2O 668 ± 10 524 ± 10 540 ± 5 457 (110 - 1174) 541 (67 - 1304) 396 ± 13 
eUosm, mosm/L 664 ± 9 526 ±11 547 ±5 450 (118 - 1142) 513 (61 - 1223) 381 ± 12 
UCI 165 ± 4 119 ± 3 117 ± 2 114 ± 2 145 ± 3 41.6 ± 3.6 
Uurea, mmol/L 285 ± 5 225 ± 5 250 ± 3 227 ± 4 296 ± 5 177 ± 6 
UNa, mmol/L 113.8 ± 2.2 79.3 ± 2.0 83.9 ± 1.0 94.8 ± 1.6 93.4 ± 1.6 68.7 ± 2.8 
UK, mmol/L 65.9 ± 1.6 63.5 ± 1.5 64.9 ± 0.8 47.4 ± 0.8 32.7 ± 0.6 33.3 ± 1.3 
eGFR . ml/min/1.73 
m2 83.4 ± 1.1 92.2 ± 0.7 89.1 ± 0.4 96.3 ± 0.6 — 46.2 ± 2.5 
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1. Generation Scotland: SFHS (GS: SFHS) and CROATIA-Korcula 
 Aberdeen and Glasgow subjects were selected from the Generation Scotland study, a 
family-based genetic epidemiology study that included 24,000 volunteers from across Scotland, 
as previously described (Smith BH. et al. 2006). Biological samples including morning spot 
urine, were collected during participation from 2006-2011 (Olden M. et al. 2014). We also 
studied subjects from the CROATIA-Korcula cohort, a family-based, cross-sectional study from 
the island of Korcula (Croatia) that initially included 965 subjects, as previously described 
(Polasek O. et al. 2009). Studies of these three cohorts included clinical information, biochemical 
measurements, and lifestyle and health questionnaires. For the present study, subjects from these 
three cohorts were randomly selected for measurement of Uosm (n = 554 from GS: SFHS 
Aberdeen, 2,305 from GS: SFHS Glasgow and 463 from CROATIA-Korcula). All participants 
provided written informed consent. For GS: SFHS national ethical approval has been obtained 
from the National Health Service Tayside Research Ethics committee. The CROATIA-Korcula 
study was approved by the Ethical Committee of the Medical School, University of Zagreb. 
 
2. SKIPOGH 
 SKIPOGH (Swiss Kidney Project on Genes in Hypertension) is a family- and population-
based cross-sectional multi-center study that examines the genetic determinants of blood 
pressure. Participants were recruited in 2009-2013 in the cantons of Bern and Geneva, and the 
city of Lausanne. Detailed methods have been previously described. (Pruijm M. et al. 2013; 
Ponte B. et al. 2014). The study visit was performed in the morning after an overnight fast. 
Participants were asked to bring urine of the previous 24 h collected separately during day and 
night periods defined according to each participant’s self-reported bedtime and wake-up time. 
The SKIPOGH study was approved by the Human Research Ethics Committee of Lausanne 
University Hospital and University of Lausanne (Lausanne, Switzerland), by the Ethics 
Committee for the Research on Human Beings of Geneva University Hospitals (Geneva, 
Switzerland), and by the Ethics Committee of the Canton of Bern, (Bern, Switzerland). 
 
3. CKD patients  
 This study includes 146 out-patients with CKD of diverse etiologies and various levels of 
renal dysfunction, attending the Nephrology Department of Necker Hospital (Paris, France) in 
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1993 for a bi-annual checkup (Jungers P. 1995; Roussel R. et al. 2015). All patients provided 24 
h urine. Informed consent was obtained for storage of the samples and additional future 
measurements to enable a more complete understanding of the pathophysiological characteristics 
related to CKD. On the freshly collected plasma and urine samples, osmolality was measured 
with a freezing point osmometer (Roebling, Berlin, Germany). Creatinine concentration was 
measured by the Jaffe colorimetric method and creatinine clearance in ml per 1.73 m2 was used 
as an estimate of GFR. Concentration of urinary solutes was measured with a classical automatic 
multi-analyzer. 
Measurements in Plasma and Urine Samples 
 In the 4 population-based cohorts, urine samples were kept frozen at -80 °C until 
measurements of Uosm and urinary solute concentrations. Sodium, potassium, glucose, creatinine, 
and urea were measured with a Beckman Coulter Synchron System Assays (Unicell DxC 
Synchron Clinical System). The CKD-EPI formula was used to calculate eGFR (van den Brand 
JA. et al. 2011) Uosm was measured on 20 µl samples by the freezing-point depression technique 
using an Advanced Osmometer (Massachusetts 02062, USA). A control (Clinitrol 290) and a set 
of calibration standards (50, 850 and 2000 mosm/kg H2O) were used before running each batch. 
The intra-assay coefficient of variability was 0.19 % and the inter-assay coefficient of variability 
was 1.32 %. 
Calculations and Statistical Analyses 
 Most modern osmometers measure the osmolality of the fluids in milliosmoles per kg 
water (mosm/kg H2O) (see footnote 1). Osmolarity expresses the concentration of osmotically 
active molecules in milliosmoles per liter of water (mosm/L). Sweeny and Beuchat described the 
technical aspects and limitations of osmometry methods and provided detailed considerations 
about the concepts of osmotic pressure, osmolarity, osmolality and solute concentrations 
(Sweeney TE. et al. 1993). 
 
Footnote 1: The terms osmolarity or osmolality should be preferred to "osmotic pressure" because 
this physical osmotic force is not a pressure. It was named in this way in the past, when osmolarity was 
evaluated indirectly as a hydrostatic pressure generated by an unknown fluid opposed to a reference fluid, 
separated by a semi-permeable membrane. The measurements were expressed in mm height between the 
levels of the two fluids in the two compartments. 
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Estimated urine osmolarity (eUosm) 
 The major urinary solutes, accounting for more than 90 % of all urinary osmoles, are urea 
and the two cations sodium and potassium along with their accompanying anions. Thus, their 
cumulated concentrations (in mmol/L) should be close to the actual Uosm (in mosm/L). An 
"estimated" Uosm (eUosm) can be calculated according to the following formula: 
  eUosm = (UNa + UK )*2 + Uurea 
Where UNa, UK and Uurea are the urinary concentrations of sodium, potassium and urea 
respectively, in mmol/L. (UNa + UK) is multiplied by 2 to account for the accompanying anions. 
If urea was measured as urea nitrogen, it should be remembered that there are two atoms of 
nitrogen (MW = 14) per molecule of urea. Urea in mmol/L = urea nitrogen in mg/dL x 0.357 
(explanation: urea nitrogen in mg/dL multiplied by 10 (conversion of dL to L) and divided by 
14x2 (mg N per mmol urea). In case of significant glycosuria, glucose concentration can be 
added to the formula. 
Urine Concentrating Index (UCI) 
 Creatinine is freely filtered and is assumed to undergo negligible secretion or 
reabsorption along the nephron when kidney function is normal. Thus, the concentration of 
creatinine in urine relative to that in plasma (Ucreat and Pcreat, respectively), i.e., the ratio of urine-
to-plasma creatinine concentrations, is proportional to the fraction of filtered water that has been 
reabsorbed to concentrate the solutes in the urine. This ratio provides an Index of Urine 
Concentration (UCI), a ratio that has no unit: 
  UCI = Ucreat / Pcreat 
Statistical analyses 
 The Statistical Package for Social Sciences (SPSS) version 19 (IBM Corporation, New 
York) and GraphPad Prism 5 were used to carry out the statistical analyses and generate the 
figures. Results are shown as means ± SEM for normally distributed variables, or as medians and 
25 % - 75 % interquartile range (IQR) for other variables. The agreement between mUosm and 
eUosm was assessed by Bland-Altman plots. The Shapiro-Wilk test was used to assess the 
distribution of mUosm in the SKIPOGH study. Correlations were studied using Pearson's 
correlation analysis (in case of normality) or Spearman’s rho test (for other variables). Wilcoxon 
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signed-rank test was used to compare repeated measures for day and night urine samples of the 
SKIPOGH subjects. The significance level was set at 5 %. 
Results 
 
Uosm surrogates in population-based cohorts 
 
Large variations in urine concentration are observed among individuals. The mUosm in 
different subjects varies from ≈ 150 to 1,200 mosm/kg H2O in spot urine of the three population-
based cohorts as well as in day and night urine of the SKIPOGH cohort (Figures 1A and 2B). A 
substantial number of subjects (21 %) dilute their urine below plasma osmolality whereas others 
(9 %) concentrate their urine up to three times more than the level of plasma osmolality (Figure 
2A). These extreme mUosm are not associated with differences in eGFR. 
 Highly significant linear correlations are observed between mUosm and eUosm in all 
populations (CROATIA-Korcula r = 0.98, GS: SFHS Aberdeen r = 0.98, GS: SFHS Glasgow r = 
0.99) (Figures 1A and 2B). The best fit linear regression lines are almost superimposed with the 
medians. 
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Figure 1: Comparison of urine osmolality surrogates with measured urine osmolality. A:. Linear correlation 
between measured osmolality and estimated osmolarity in 3 cohorts. CROATIA-Korcula: mUosm = 1.03 
eUosm + 3.3 (p < 0.001, r = 0.98); GS:SFHS Aberdeen: mUosm = 0.99 eUosm – 4.4 (p < 0.001, r = 0.98); 
GS:SFHS Glasgow: mUosm = 0.96 eUosm + 11 (p < 0.001, r = 0.99). The thin vertical lines show mUosm 
of 300 and 900 mosm/kg H2O, i.e. approximatively one time and three times the plasma osmolality. B:. 
Quadratic correlation between UCI and measured urine osmolality in 3 cohorts. CROATIA-Korcula: 
mUosm = 5.04 UCI – 0.009 UCI2 + 126 (p < 0.001, r = 0.76); GS:SFHS Aberdeen: mUosm = 5.52 UCI – 
0.009 UCI2 + 28 (p < 0.001, r = 0.90); GS:SFHS Glasgow: mUosm = 4.89 UCI – 0.006 UCI2 + 90 (p < 
0.001, r = 0.89). Black lines represent the best-fit curves. Red thin lines represent the 95 % confidence 
intervals. Dotted lines in the top panel represent the medians. 
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Figure 2: Day-time and night-time urine in the SKIPOGH population (n = 925). A: Distribution of mUosm 
among SKIPOGH subjects. Thin curves represent the normal distribution model. B: Linear correlation 
between measured and estimated Uosm in daytime and night-time urine. C: Quadratic correlation between 
UCI and mUosm in daytime versus night-time urine. In B and C, black lines represent the best-fit curves 
and red thin lines 95 % confidence intervals. Dotted lines in B represent the medians. 
 
Bland-Altman plots show a good agreement between eUosm and mUosm in the three population 
based cohorts (Table 1). This is reflected in the small bias values (CROATIA-Korcula bias = 24, 
GS: SFHS Aberdeen bias = -6, GS: SFHS Glasgow bias = -23), and relatively narrow precision 
range (CROATIA-Korcula -44 to 90, GS: SFHS Aberdeen -54 to 43, GS: SFHS Glasgow -80 to 
34). Plot for the GS: SFHS Aberdeen population is given as an example in Figure 3. 
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Figure 3: Bland-Altman plots showing the agreement between estimated and measured Uosm in the spot 
urine samples of GS:SFHS Aberdeen (top), the day urine samples of SKIPOGH (middle) and the 24 h urine 
of the CKD patients. 
 
Although the relations between UCI and mUosm are significant, they exhibit a relatively large 
dispersion of individual values, increasing with increasing osmolality (Figures 1B and 2C). 
Nonetheless, as an average, the ratio of UCI to mUosm is fairly constant (0.20, 0.21 and 0.22 for 
mUosm = 300, 600 and 900 mosm/kg H2O, respectively). UCI can be approximately converted to 
osmolality by the following quadratic formula: mUosm = 5 UCI – 0.007 UCI2 + 83. 
 The possible influence of glycosuria that occurred in some subjects on eUosm was 
evaluated. Among 3,322 subjects of the three cohorts in which urinary glucose was available, 58 
exhibited glucosuria > 1.66 mmol/L [41] (mean ± SEM 11.58 ± 2.28 mmol/L; range 1.7 to 86.8). 
Their age and eGFR were 57.0 ± 1.8 y and 86.8 ± 2.4 ml/min, 1.73 m2, respectively. Measured 
Uosm in these subjects was 642 ± 32 mosm/kg H2O. Estimated Uosm, calculated without or with 
the addition of urinary glucose was 624 ± 31 and 635 ± 32 mosm/L respectively, both within 3 % 
of mUosm. 
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 Urine osmolality is known to be higher in men than in women. This was verified in the 
cohorts of the present study (Table 2): men exhibited higher mUosm and eUosm than women 
although the magnitude of this gender difference differed among the three populations. eUosm 
was very close to mUosm in both genders and the men/women ratio of eUosm was very similar to 
that of mUosm. For UCI, there was a tendency for more inter-individual variation in women than 
in men as well as lower men/women ratios which tended to underestimate the gender difference. 
Uosm surrogates in day and night urine 
 In healthy subjects, urine is usually more concentrated during the night than during the 
day. We investigated if the relationships between mUosm, eUosm and UCI are comparable in day 
and night urine of the 925 subjects of the SKIPOGH study (Figure 2A). The Shapiro-Wilk test 
indicates that these variables diverge from a normal distribution (shown by a thin curve). Mean 
mUosm ± SEM during day and night was respectively 520 ± 4 and 572 ± 7 mosm/kg H2O. 
Median (IQR) values were 457 (334 – 676) and 541 [356 - 777] mosm/kg H2O, respectively (p < 
0.001, Wilcoxon signed-rank test). The histograms of mUosm during day and night do not follow 
a normal distribution and there is a tendency for a bimodal distribution during the night. 
 
 Measured and estimated Uosm values exhibit highly significant linear correlations in both 
day and night urine (Figure 2B), as also observed in the spot urine of the other cohorts. Bland-
Altman plots show a good agreement between eUosm and mUosm in day and night urine, as 
reflected by the small bias values (day bias = 9, night bias = 24), and the precision range (day -71 
to 89, night -66 to 114) (Figure 3). The relations between UCI and mUosm are best described by 
quadratic correlations. Thin red lines show the 95 % confidence intervals. As in the three cohorts 
shown in Figure 1, UCI vs mUosm values were more widely dispersed than eUosm vs mUosm 
values. 
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Uosm surrogates in CKD patients 
 
Table 2 compares the values of eUosm and UCI to those of mUosm in CKD patients, according to 
their level of renal function. In all CKD classes, eUosm is very close to mUosm. Both variables 
decline in parallel with declining eGFR. Bland-Altman plot show a relatively good agreement 
between the two methods, as reflected by the small bias value (15) and the precision range (37 to 
67) (Figure 3). In contrast, UCI declines much more dramatically than mUosm. These differences 
are due mostly to the progressive rise in plasma creatinine concentration (from 91 ± 5 to 514 ± 
34 µmol/L in the two extreme classes, a 5.6 fold increase) while urine creatinine concentration 
declines only two-fold as a result of a lower total creatinine excretion and a moderately higher 24 
h urine volume. In these patients, a spot urine sample was collected in the morning following the 
24 h urine collection (Table 2). mUosm in morning urine is 10 - 20 % higher than mUosm in 24 h 
urine, a difference that seems independent of the level of renal function. 
 
 
Table 2: Osmolality and its surrogates in 147 CKD patients according to the level of renal function 
Means ± SEM. CKD stages are shown with the limits of eGFR in ml/min per 1.73 m2. 
Spot mUosm = mUosm of a morning spot urine sample. All other values concern 24 h urine collection. 
(1) For the ratio of UCI/mUosm. UCI was multiplied by 100 to make the reading easier. 
  
CKD Stage N 
Creatinine 
Excretion 
Spot 
mUosm mUosm eUosm 
eUosm / 
mUosm UCI 
UCI*100 / 
mUosm 
   mmol/d 
mosm/kg 
H2O 
mosm/kg H2O mosm/L  
(Ucreat 
/Pcreat) 
(1) 
         
Stage 1 ( > 90) 13 13.4 ± 1.0 738 ± 61 650 ± 48 608 ± 43 0.94 ± 0.01 146 ± 17 22.1 ± 1.6 
Stage 2 (60 - 89) 29 13.2 ± 0.7 517 ± 32 479 ± 34 458 ± 34 0.95 ± 0.01 59 ± 5 12.3 ± 0.4 
Stage 3 (30 - 59) 54 11.5 ± 0.5 450 ± 14 371 ± 14 358 ± 14 0.97 ± 0.01 34 ± 2 9.2 ± 0.3 
Stage 4 (15 - 29) 32 9.4 ± 0.5 376 ± 13 321 ± 13 311 ± 12 0.98 ± 0.01 17 ± 1 5.2 ± 0.3 
Stage 5 ( < 15) 19 8.1 ± 0.5 318 ± 11 296 ± 12 291 ± 12 0.98 ± 0.02 7 ± 1 2.5 ± 0.2 
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Discussion 
 
 The urine concentrating activity of the human kidney was rarely investigated, except in a 
few conditions such as urolithiasis and diabetes insipidus. Recent experimental and 
epidemiological findings have renewed the interest in the components of the water balance and 
in the parameters reflecting this integrative function (Bouby N. et al. 1990; Perico N. et al. 2009; 
Torres VE. 2009; Clark WF. et al. 2001; Strippoli GF. et al. 2011; Bankir L. et al. 2013; Devuyst 
O. et al. 2013; Perrier E. et al. 2013; Zittema D. et al. 2014; Perrier ET. et al. 2015; Ponte B. et 
al. 2015). It is indeed quite different for the kidney to excrete a daily osmolar load of 900 mosm 
in 1 L of urine at 900 mosm/L or in 3 L of urine at 300 mosm/L. Increased urine concentration 
(associated with increased solute-free water reabsorption) results in a lower fractional excretion 
of several solutes and in a significant hyperfiltration that is, at least in part, mediated by 
vasopressin acting on renal V2 receptors. It has been proposed that this hyperfiltration is 
mediated by changes in the composition of the tubular fluid at the macula densa, resulting from 
vasopressin's action on water, sodium and urea transport in the collecting duct and the resulting 
recycling of urea in the medulla (Bankir L. et al. 2013). Uosm, the most direct reflect of the urine 
concentrating activity, is rarely measured in large cohorts because of technical issues (see 
below). The present study, in a cross-sectional design, describes two practical, easily accessible 
surrogates of Uosm and assesses their validity by comparing the results to the actually measured 
Uosm in large cohorts of the population and in a group of patients with CKD. We also checked the 
value of these surrogates in various sample types (spot or 24 h, day and night), and according to 
gender and to renal function. 
 
Our results show that the estimated Uosm, based on sodium, potassium and urea 
concentrations, is an excellent surrogate of the measured Uosm. In most cases, eUosm is within ± 5 
% of mUosm. This is similarly true in men and women, as well as in urine collected during day or 
night, and in patients with impaired renal function at any level of GFR. One may wonder how 
eUosm and mUosm may be so close when the formula used for the calculation of eUosm neglects the 
minor solutes that should, however, represent more than 5 % of all urinary solutes. This is partly 
explained by the fact that the units are not the same. eUosm is expressed in mosm/L while mUosm 
is in mosm/kg H2O. Because one liter of water with dissolved solutes weights more than 1 kg, 
the osmolality is lower than the osmolarity. The two measures differ only modestly for solutions 
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within the biological range. For example, a solution containing 140 mmol/L NaCl and 500 
mmol/L urea has an osmolarity of 780 mosm/L and an osmolality of 751 mosm/kg H2O (i.e. 3.7 
% lower). This difference partially compensates for the missing solutes and thus contributes to 
the almost equality of eUosm and mUosm. Another factor is that electrolytes are assumed to be 
totally dissociated in the eUosm formula. Although the dissociation is high in solutions within the 
physiological range, it is less than 100 %, thus also contributing to modestly overestimate eUosm. 
 
UCI is a less accurate reflection of mUosm than eUosm because creatinine is known to 
undergo some secretion as well as some reabsorption along the tubule. The net result of these 
opposite effects depends on the rate of urine flow (Bouby N. et al. 1996). Our study shows that 
individual values are fairly dispersed and the correlations between the two variables are not 
linear. However, when no other approach is available, UCI remains a possible surrogate of urine 
concentration, provided it is applied to subjects with normal renal function. As clearly 
demonstrated in the present study, UCI diverges markedly from mUosm in patients with CKD - 
limiting its use when renal function is impaired and probably also when abnormal handling of 
creatinine or excessive 24 h intake of creatine are suspected. 
 
A few alternative methods for quantifying urine concentration have been used. Urine 
density (UD) (or specific gravity) may be evaluated in 7 coloured grades with commercially 
available dipsticks (Labtix 8SG and Multistix 8SG AMES/Bayer Diagnostics) or evaluated by 
refractometry using a hand-held refractometer (Pen Urine S.G., Atago, Tokyo, Japan) (Bottin JH. 
et al. 2016). In the D.E.S.I.R. study (a cohort of the French population), UD was measured with 
dipsticks in fresh spot morning urine samples from 1604 subjects, and eUosm was calculated 
(same formula as here) (Roussel R. et al. 2014). Median (IQR) eUosm was 664 (272) mosm/L. 
UD was well correlated with eUosm (r = 0.446, P < 0.00001). Another study showed that UD was 
well correlated with measured Uosm but the wide dispersion made it "impossible to use UD as a 
dependable clinical estimate of Uosm" (Souza AC. et al. 2015). Moreover, UD or specific gravity 
cannot be used if urine contains proteins or glucose (Leech S. et al. 1987). 
 
 It is important to note that Uosm varies greatly among different subjects, as shown in the 
four populations of the present study and in a few previous reports (Perucca J. et al. 2007; Perrier 
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E. et al. 2013). In usual conditions, some subjects produce hypo-osmotic urine while others show 
Uosm up to 1200 mosm/kg H2O. This wide range of spontaneous Uosm is possibly due to large 
inter-individual variations in the daily solute load (Berl T. 2008), in fluid intake (Perrier E. 2013) 
and in thresholds for vasopressin secretion and/or thirst that are, in part, genetically determined 
(Zerbe RL. et al. 1991). Both vasopressin concentration and urine osmolarity are known to differ 
between sexes. Men have higher vasopressin/copeptin levels (Share L. et al. 1988; Ponte B. et al. 
2015; Roussel R. et al. 2016) and higher Uosm than women (Perucca J. et al. 2007). This 
difference is mostly due to the fact that men excrete a larger osmolar load than women with a 
higher urine osmolality but an approximatively similar 24 h urine volume (Perucca J. et al. 2007; 
Perinpam M. et al. 2006). Therefore, in studies using these variables, data for the two sexes are 
often presented separately. We verified here the validity of the two surrogates in each gender. 
For both genders, the relation between eUosm and mUosm is highly significant and the regression 
line between these two variables is very close to the identity line. The UCI also reflected this 
gender difference but tended to underestimate it slightly, possibly because of the known 
difference in creatinine handling in men and women. 
 
Differences in the usual urine concentration may be associated with the ethnic 
background. A few studies showed that African Americans tend to concentrate urine about 20 % 
more than Caucasians and have higher vasopressin levels (Cowley AW. Jr. et al. 1987; Bankir L. 
et al. 2007; Chun TY. et al. 2008). To our knowledge, very few studies have evaluated other 
possible differences in usual urine concentration related to habitat or ethnic background (Katz 
AI. et al. 1965; Kristal-Boneh E. et al.1968; Berlyne GM. et al. 1976; Taylor GO. et al. 1978; 
Johnson RH. et al. 1988). 
 
 The results of the SKIPOGH study illustrate the fact that urine is usually on the average 
more concentrated during the night than during the day by about 50 - 100 mosm/kg H2O. Few 
studies have investigated day and night urine separately (Bankir L. et al. 2008; Kimura G. et al. 
2010; Guerrot D. et al. 2011). They showed that the circadian pattern of urine flow rate/urine 
concentration and/or sodium excretion rate may be disturbed in some subjects. An excessive 
urine concentration during daytime, limiting sodium and/or water excretion rate, is subsequently 
compensated at night by the pressure-natriuresis mechanism (Burnier M. et al. 2007; Bankir L. et 
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al. 2008; Kimura G. et al. 2010; Guerrot D. et al. 2011; Fezeu L. et al. 2014). Accordingly, 
measurement of urine osmolality in overnight urine samples may not be representative of 24 h 
urine. 
There are several advantages of using surrogates of urine osmolality. Osmometers, based 
on either freezing point depression or vapor pressure methods, are expensive and rarely equipped 
with automatic sample changers. Each measurement lasts a minute or two (due to the time 
needed to freeze or heat the sample, respectively), thus allowing some evaporation if samples are 
loaded into the changer in advance. We tested the automatic changer and observed that mUosm 
values in the same sample increased after 10 loads. In studies, involving a large number of 
subjects in which individual measurements are practically impossible, values may increase 
artifactually depending on the timing of the measurements. Moreover, osmolality measurements 
cannot be coupled with measurements of various solutes performed by automatic analyzers; they 
thus require separate aliquots and time-consuming manipulations. The excellent correlation 
between eUosm and mUosm, over the whole range of mUosm values, even in CKD, validate eUosm 
as an appropriate surrogate of mUosm, especially in large cohorts. 
 
Urine electrolytes are often available in epidemiological studies, but urea, needed for the 
calculation of eUosm, is less frequently measured. When new measurements are initiated on 
previously stored samples in order to evaluate the kidney's concentrating activity, authors should 
consider the respective advantages of measuring either osmolality or urea concentration. Urea is 
much easier, quicker and cheaper to measure than osmolality. Moreover, it will also provide data 
for a significant solute in the urinary concentrating process, and allow an indirect evaluation of 
protein intake. 
 
 This study has some limitations. It concerns exclusively subjects of European descent. 
Studies in subjects of other ethnic backgrounds are required. The possible influence of socio-
demographic factors has not been considered. However, we think it is reasonable to assume that 
the highly significant correlations between eUosm and mUosm, and the relatively good 
relationships of UCI with mUosm are not dependent upon the population under study and may be 
extended to all populations, as long as the measurements of sodium, potassium, urea and 
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creatinine concentrations are performed in appropriately equipped laboratory with rigorous 
methods. 
 
 In summary, the present study validates, in large cohorts, the use of an estimated 
osmolarity based on the measurement of sodium, potassium and urea, as an excellent surrogate 
of the measured urine osmolality. It also shows that the urine concentrating index, based on the 
ratio of creatinine concentrations in plasma and urine, may be used as a relative index of urine 
concentration only in subjects with normal renal function because of the disturbed handling of 
creatinine in CKD. In contrast, eUosm is valid whatever the level of renal function. In future 
epidemiologic studies addressing the influence of vasopressin and urinary concentrating activity, 
the use of the estimated urine osmolarity should be recommended when the actual urine 
osmolality cannot be measured. 
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VII. Discussion and Outlook 
 
In this work, we validated an in-house immunoassay to establish a standardized procedure for the 
measurement of uromodulin in the urine. We explored biochemical modifications of this 
glycoprotein caused by a common variant in the UMOD promoter. We used the in-house 
uromodulin assay in different cohorts in order to identify clinical and genetic factors that 
modulate uromodulin excretion in the general population. These results contributed to the 
validation of uromodulin as a biomarker for tubular mass and function in the general population. 
They also evidenced factors important for its excretion in the urine. Taken together, these results 
yielded insight into the physiological roles and value of uromodulin as a biomarker. 
 Despite its long history, a clear understanding of the complex physiological role of 
uromodulin is still lacking (Devuyst O. et al. 2017). The growing interest in the physiology of 
uromodulin and its potential value as biomarker required the availability of a robust and faithful 
method to measure its level in the urine from large cohorts. Thus, a high-throughput and cost-
effective immunoassay assay to measure uromodulin were needed, as well as the clarification of 
issues related to storage and handling of urine samples to perform the assay. 
 In the first part of this thesis, we described an immunoassay with a linear standard curve 
over a broad range of values, allowing the detection of uromodulin with high sensitivity and very 
low inter- and intra-assay variability. After characterizing and validating this assay, we used it as 
a tool to investigate the stability of uromodulin in human urine under different treatment and 
storage conditions. We showed that urinary uromodulin levels were significantly decreased by 
centrifugation (~30 %) which might be clinically misleading in some patients (Rampoldi L. et al. 
2011; Bollée G. et al. 2011; Dahan K. et al. 2003; Bleyer AJ. et al. 2004). On the other hand, we 
showed that vortexing is necessary since it helps to recover uromodulin that tends to aggregate 
(Zhou H. et al. 2011) and to get trapped in the cell debris (Uto I. et al. 1991). Conflicting results 
were reported concerning sample treatment prior to dosage in order to solubilize uromodulin 
(Akesson I. et al. 1978; Uto I. et al. 1991; Torffvit O. et al. 1992; Kobayashi K. et al. 2001; 
Dawney AB. et al. 1982). Knowing that some of the employed treatments could affect the 
binding of uromodulin to the ELISA capture antibody we demonstrated that diluting urine 
sample with deionized water yields similar results as dilution with TEA buffer. 
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 Studying the stability of uromodulin under different storage condition is crucial, 
particularly when analyzing a large number of samples from multicentric cohorts. Prior studies 
regarding the influence of storage duration and temperature on uromodulin levels were conflicted 
by small sample size (Akesson I. et al. 1978; Uto I. et al. 1991; Torffvit O. et al. 1992; 
Kobayashi K. et al. 2001) and lack of normalization for urinary creatinine (Waikar SS. et al. 
2010; Ortiz A. et al. 2011). We showed on a large number of samples that indexed uromodulin 
levels were influenced by short (1 week) and long storage period independent of temperature 
(room temperature, 4 °C or -20 °C) revealing a significant decrease in uromodulin levels. These 
results were in line with the observations of Kobayashi (Kobayashi K. et al. 2001). The 
degradation effect can be partially mitigated by adding protease inhibitors to samples stored at -
20 °C. We observed a negligible and non-significant decrease in the unindexed and indexed 
uromodulin values in samples that were stored at -80 °C for 4 months. In contrary, a significant 
decrease in unindexed uromodulin levels was observed after 8-month storage at -80 °C. 
Moreover, freezing and thawing samples on ice up to 5 times did not affect the stability of 
uromodulin stored at -80 °C. 
 These results established a robust immunoassay, which displays a wide detection range of 
uromodulin levels, together with low variability and low cost. They proved that reliable 
measurement of uromodulin could be obtained when urine samples are stored at -80 °C and 
analyzed within 3 months with vortexing and using only water for dilution. This procedure is 
suitable for high-throughput investigations of uromodulin and its validation as a biomarker for 
renal function and risk of CKD. 
 In the second part of the thesis, we investigated the effect of a common variant 
(rs1297707) in the promoter region of UMOD on the levels of uromodulin in urine and blood as 
well as on the biochemistry of this protein. The regulatory effect of the UMOD promoter variants 
on the transcription and urinary levels of uromodulin is well established (Trudu M. et al. 2013; 
Olden M. et al. 2014). However, a possible influence of these variants on the biochemical 
features of uromodulin and on its circulating levels is still unknown. 
  Several studies corroborated that the major alleles (risk alleles) of GWAS-identified 
common variants in the promoter region of UMOD are in total LD with the variant rs12917707 
and are associated with increased risk for several renal disorders in the general population 
(chronic kidney disease, kidney stones and hypertension) (Köttgen A. et al. 2009; Köttgen A. et 
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al. 2012; Padmanabhan S. et al. 2010; Reznichenko A. et al. 2012). Moreover, these risk alleles 
were correlated with elevated urinary uromodulin levels (Olden M. et al. 2014) indicating that 
elevated uromodulin levels were linked to higher predisposition to certain renal disorders. In this 
work, carried out in Swiss cohorts, we showed that the risk allele G of variant rs12917707 
resulted in higher uromodulin levels in comparison to the minor allele, independent of 
normalization to creatinine. We also showed that the UMOD variant rs12917707 regulated 
changes in plasma uromodulin levels: Higher circulating uromodulin levels were observed in 
subjects harbouring the major allele (G) when compared to age and gender-matched subjects 
harbouring the minor allele (T). Of note, plasma uromodulin levels were approximately 1000-
fold lower than the urine levels. We were the first to investigate modulators of circulating 
uromodulin levels by showing plasma uromodulin together with urine uromodulin in the same 
population with regards to the genotype of UMOD variant. In a recent study, Graciela et al. 
(Graciela E. et al. 2017) explored plasma uromodulin as a biomarker for cardiovascular diseases 
and reported higher plasma uromodulin levels in the presence of risk allele for rs12017707. 
However, they did not analyze urine uromodulin levels in the same population. We suggested 
that high levels of circulating and urine uromodulin levels associated with the UMOD risk allele 
could be an early indicator of tubular dysfunction, which may precede damage in the tubular 
interstitium. 
 We next tested whether UMOD promoter variants, which are located in a strong LD 
block comprising exons 3, 4 and 6, are also changing the glycosylation pattern of uromodulin. 
Uromodulin harbours seven sites for N-glycosylation, a post-translational modification that is 
essential for its functions, such as binding to type I fimbriated Escherichia coli (Bates JM. et al. 
2004). Possible genotype-related changes in glycosylation patterns might affect the interactions 
of uromodulin with uropathogenic E. coli, thus modulating the propensity for urinary tract 
infections (UTIs). Based on age- and gender-matched urine samples, we identified differences in 
immunoreactivity as well as in isoelectric point (IP) among genotypes: The minor allele T 
samples had lower immunoreactivity and higher IP when compared to sample from the major 
allele G. However, we were able to eliminate these discrepancies with de-N-glycosylation which 
hinted towards divergences in N-glycan composition. We confirmed the effect of UMOD 
genotype through completing N-glycan profiling by MS-MALDI in matched urine samples. The 
differences in N-glycosylation were not caused by modifications in the coding sequence of 
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UMOD (Köttgen A. personal communication). Instead, we hypothesized that alteration in the 
glycan composition might reflect a mechanism of adaptation by the cell machinery to the 
increased production of uromodulin when the risk allele is present. Considering the limited 
number of matched samples analyzed, further studies are necessary to elucidate the effect of 
UMOD variant on uromodulin N-glycosylation and its potential consequences on the biology of 
the protein in the urine. 
 In the third part of the thesis, we investigated the clinical and genetic factors modulating 
uromodulin excretion in the general population. These investigations were carried out in three 
large cross-sectional studies from Switzerland (SKIPOGH, CoLaus) and Canada 
(CARTAGENE). We found a positive correlation between uromodulin excretion levels and renal 
mass, renal volume, eGFR and urine parameters, indicating that uromodulin levels reflect tubular 
mass and tubular function. Urine uromodulin was also associated with urine osmolality, 
parameter that reveal tubular activity, which supports uromodulin as a good marker of tubular 
activity. These outcomes supported findings from previous studies (in vitro and in vivo) that 
showed uromodulin as a modulator of transport processes in the TAL by enhancing ROMK 
activity and increasing the phosphorylation of NKCC2 processes thus affecting urine 
concentrating ability (Renigunta A. et al. 2011; Mutig K. et al. 2011). Conversely, age and 
glycosuria were negatively associated with uromodulin levels, which might also reflect tubular 
damage. It has been shown that glycosuria modulates the TAL activity consequently uromodulin 
excretion (Riazi S. et al. 2006). Our results were in line with a study on CKD patients with 
diabetes but without glomerular dysfunction (Möllsten A. et al. 2010). Validation of these 
findings in a large diabetic-specific study is necessary. Furthermore, genetic variants positioned 
in the UMOD promoter and the PDILT genes were implicated in regulating the urinary levels of 
uromodulin. 
 The positive association we identified among uromodulin levels and kidney structural 
parameters, functional indicators as well as urinary electrolytes and osmolality on one hand and 
the negative association with age and glycosuria on the other hand, validated uromodulin as a 
biomarker for tubular mass and tubular function in the general population. These solid 
associations specifically with urine electrolytes, eGFR and osmolality were consistent whether in 
24 h or spot urine. Our findings complemented previous studies that were conducted in specific 
groups of patients with renal diseases such as autosomal dominant polycystic kidney disease, 
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diabetic nephropathy, and tubulointerstitial nephritis. This study has many advantages: studied 
populations had a large sample size in addition to the detailed information about participants. 
Uromodulin measurements, as well as urine parameters, were carried out in one center using a 
well-established method. Renal length and renal mass measurements were achieved using 
standardized protocol. As limitations, this study lacked the ethnic diversity and the limitation in 
assessing causal conclusions because these are cross-sectional studies. 
 In a final part, we tested the validity of two surrogates for urine osmolarity: the estimated 
urine osmolarity (eUosm) which is determined from the concentration of three main urinary 
parameters: sodium, potassium and urea (Perucca J. et al. 2007; Zittema D. et al. 2014), and the 
urine concentrating index (UCI), which depends on the handling of creatinine by the kidney 
(Perucca J. et al. 2007; Bankir L. et al. 2007). Since these parameters have not been validated, 
we assessed eUosm and UCI compared to measured Uosm (mUosm) in large population-based 
and CKD cohorts. We also studied the effect of gender, age and sample type (spot or 24 h, day 
and night) on these surrogates. 
 We showed that eUosm is a good surrogate for mUosm with a difference ± 5 %. 
These findings were independent of gender, urine type (day and night) and renal function 
(measured with eGFR). The differences between eUosm and mUosm were caused by solutes that 
were not considered when using the eUosm formula and also because in this formula electrolytes 
were considered to be totally dissociated whereas in reality, this dissociation is less than 100 % – 
both factors leading to a slight overestimation of eUosm. These results were in line with results 
from the D.E.S.I.R. study in which urine density (UD) correlated significantly with eUosm in 
fresh spot morning urine samples from 1,604 subjects (r = 0.446, P < 0.00001) (Roussel R. et al. 
2014). Another study showed that UD correlated with measured Uosm but with a wide 
dispersion (Souza AC. et al. 2014). Our results also showed that UCI is an acceptable surrogate 
for urine concentration showing non-linear correlation with mUsom. UCI was less accurate than 
eUosm in reflecting mUosm since urine creatinine values depend on the urine flow rate that 
affects creatinine secretion and reabsorption along the tubule (Bouby N. et al. 1996). 
Nevertheless, UCI can still be considered as surrogate for urine osmolarity when other 
approaches are not available. This measurement deviated noticeably from mUosm in patients 
with CKD, which limits its use to subjects with normal renal function. 
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 We observed a large variability in Uosm levels among subjects from the four studied 
populations. This variability is induced by the inter-individual variations in daily solute and fluid 
intake (Pierre E. et al. 2013; Berl T. et al. 2008) also by vasopressin secretion and/or thirst that 
are genetically determined to some degree (Zerbe RL. et al. 1999). Besides vasopressin 
concentration and urine osmolarity differ between men and women: men have higher 
vasopressin/copeptin levels (Share L. et al. 1988; Ponte B. et al. 2015; Roussel R. et al. 2016) 
and higher Uosm compared women (Perucca J. el al. 2007). The significant correlation between 
eUosm and mUosm that covered a wide range of mUosm values, even in CKD, corroborated 
eUosm as a suitable surrogate for mUosm. Particularly surrogates are useful in investigations of 
large cohorts, where separate measurements tend to overestimate Uosm because of time thus 
making these measurements practically impossible in addition to time-consuming manipulations. 
This study had a limitation: it concerned exclusively subjects of European origin. Studies in 
subjects with different ethnic backgrounds are necessary. 
 
Conclusion: In this thesis, we provided a robust and cost-effective assay for determination of 
uromodulin levels in the urine, with appropriate validation of sampling and experimental 
procedures. Based on this assay, we could substantiate the value of uromodulin as a biomarker 
for kidney tubular mass and function in the general population. We also provided novel 
indication that UMOD promoter variants not only influence the absolute levels of uromodulin 
production and secretion, but also its glycosylation pattern. These findings need further 
explorations to identify the mechanisms regulating the production and biochemical maturation of 
uromodulin, and its release at the apical and basolateral side of the cells lining the TAL in the 
kidney. These studies are important to better understand the relationship between uromodulin 
structure and the transport activity in the TAL and, more generally, the physiological role of this 
protein. 
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Teaching assistant at University of Zurich: First and second year medical students in the 
following: Central Nervous System, ECG, signal transduction and respiration. 
 
2008 - 2010:  
Practicum lecturer at Lebanese American University: General Biology course for biology 
students 
 
Awards 
 
2012: Travel grant from International Society of Nephrology 2012 
 
Poster presentations  
 
 
2016: 6th Kidney – Control of Homeostasis Retreat 
2015: National Centres of Competence in Research Kidney.CH Retreat 
2014: National Centres of Competence in Research Kidney.CH Retreat 
2013: National Centres of Competence in Research Kidney.CH. Retreat 
2013: National Centres of Competence in Research Kidney.CH. Site visit in Zurich 
2012: National Centres of Competence in Research Kidney.CH. Retreat 
2012: SSN/SGN Annual Meeting Zurich 
2012: International Society of Nephrology. Ann Arbor, Michigan, USA 
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